

## PERSISTENT BACTERIAL INFECTIONS: THE INTERFACE OF THE PATHOGEN AND THE HOST IMMUNE SYSTEM

Denise M. Monack, Anne Mueller and Stanley Falkow

**Abstract** | Persistent bacterial infections involving *Mycobacterium tuberculosis*, *Salmonella enterica* serovar Typhi (*S. typhi*) and *Helicobacter pylori* pose significant public-health problems. Multidrug-resistant strains of *M. tuberculosis* and *S. typhi* are on the increase, and *M. tuberculosis* and *S. typhi* infections are often associated with HIV infection. This review discusses the strategies used by these bacteria during persistent infections that allow them to colonize specific sites in the host and evade immune surveillance. The nature of the host immune response to this type of infection and the balance between clearance of the pathogen and avoidance of damage to host tissues are also discussed.

### INNATE IMMUNE RESPONSE

A cellular defence reaction that counteracts invading pathogens, such as bacteria and viruses. It uses interferon-dependent signalling and leads to the activation of genes that are responsible for bactericidal or antiviral responses.

### ADAPTIVE IMMUNE RESPONSE

This involves specificity and immunological memory. It is mediated by T and B cells through the activation of cytotoxic CD8<sup>+</sup> T cells for pathogen killing or by interaction with CD4<sup>+</sup> T cells for antibody production.

Department of Microbiology and Immunology, Stanford School of Medicine, Stanford University, Stanford, California 94305, USA.  
Correspondence to D.M.M.  
e-mail: dmonack@leland.stanford.edu  
doi:10.1038/nrmicro955

When a pathogenic microorganism first infects its host, there is usually a dramatic activation of the INNATE and ADAPTIVE immune responses, which can result in disease symptoms. If the pathogen and the host survive this initial interaction, the adaptive host immune system usually clears the invading offender. However, some pathogenic bacteria are capable of maintaining infections in mammalian hosts even in the presence of inflammation, specific antimicrobial mechanisms and a robust adaptive immune response, and can therefore be described as giving rise to persistent infection<sup>1,2</sup> (BOX 1; see TABLE 1 for a list of bacteria that cause persistent infections in humans). For example, *Helicobacter pylori* inhabits the human gastric mucosa and persistence of this bacterium in its host can be life-long<sup>3</sup>; *Mycobacterium tuberculosis* can establish long-term infections that can manifest as acute or chronic disease, or can be clinically asymptomatic with the potential to become reactivated later<sup>4,5</sup>; and *Salmonella enterica* serovar Typhi (*S. typhi*) causes systemic infection (typhoid fever) that involves colonization of the RETICULOENDOTHELIAL SYSTEM (RES). Some individuals who are infected with *S. typhi* become life-long carriers, periodically shedding large numbers of bacteria in their stools. Persistently infected carriers serve as the reservoir for these pathogens, and the carrier state is

an essential feature that is required for survival of the bacteria within a restricted host population.

Persistent colonization with these bacterial pathogens is usually not clinically apparent. However, even in the absence of clinical symptoms, infection poses some risk to the host. Individuals who are infected with *M. tuberculosis* are at risk of reactivation of the pathogen to produce an active disease state that can be life-threatening. A significant proportion of people who are infected with *H. pylori* develop peptic or duodenal ulcers, or even gastric cancer<sup>6</sup>. In addition, individuals carrying *S. typhi* have an increased risk of developing hepatobiliary cancer<sup>7</sup>. The long-term residence of the bacteria in a privileged host niche — such as the MACROPHAGE vacuole or gastric mucosal layer — poses several fundamental biological questions. For example, what is the replicative and metabolic state of the bacteria during persistent asymptomatic infection, and how do these organisms manage to escape clearance for so long in the presence of the host immune response? We are only now beginning to understand the bacterial and host factors that are involved in the host–pathogen interaction during persistent infection, and the answers to these questions are likely to provide new and exciting directions for research in the fields of microbial pathogenesis and immunology.

## Box 1 | Persistence versus commensalism

When thinking about persistent bacterial infections, it is important to keep in mind the distinction between bacteria that are true commensals or part of our normal flora and those that can cause disease symptoms in certain circumstances. We believe that bacterial pathogens that are capable of persisting in a human host for long periods of time fall into at least two classes, both of which have characteristics that distinguish them from commensal species.

One class is defined by a group of organisms that, after causing an initial disease state, are kept in check by an adaptive immune response, but are not completely cleared from the host and persist in a privileged niche — perhaps inside host cells — for long periods of time. Examples of such species are *Helicobacter pylori*, *Salmonella enterica* serovar Typhi and *Mycobacterium tuberculosis*.

A second class of persistent bacterial pathogens are carried asymptotically in the nasopharynx in most people among the commensal flora, although they still have the ability to cause life-threatening disease in seemingly immunocompetent individuals. *Streptococcus pneumoniae*, *Neisseria meningitidis* and *Haemophilus influenzae* type B are perhaps the best-known members of this group. All of us at some time in our life are colonized, typically asymptotically, by these species. The host and bacterial factors that contribute to the disease state are unknown, but the epidemiology of meningitis caused by *S. pneumoniae* and *N. meningitidis* shows that it is caused by the acquisition of a new serotype of the same species, rather than by superinfection with the strain that is already present<sup>216</sup>.

How do the organisms in this second class of persistent bacteria colonize the human nasopharynx in an apparently silent manner? The virulence mechanisms of these organisms usually involve antiphagocytic capsules, immunoglobulin A (IgA) protease and antigenic variation of outer-membrane proteins<sup>217</sup>. However, an intriguing hypothesis that can be overlooked in this focus on disease is that these pathogenicity determinants have evolved to allow the bacteria to colonize deeper tissues in the nasopharynx, and not just the mucosal surfaces as organisms of the normal flora do. We propose that these organisms use virulence factors to penetrate the mucosal barrier and become resident in the nasopharyngeal-associated lymphatic tissue (NALT)<sup>218</sup> in the same way that *Salmonella* persists in the mesenteric lymph nodes adjacent to the Peyer's patches. In this way, the persistent bacteria in the NALT can re-seed the mucosal surface, which is constantly exposed to host cleansing mechanisms, such as those involving neutrophils and IgA. The trigger that causes colonization to go awry and develop into disease is presumably a combination of both host and pathogen physiological and genetic factors that shifts the delicate balance.

The ability to cause persistent infection is a fundamental aspect of the interaction between many diverse viral, bacterial and eukaryotic pathogens and their mammalian hosts. This review is not intended to address all or even a significant proportion of these pathogens. Rather, we will discuss several aspects of three persistent bacterial pathogens: *H. pylori*, a predominantly extracellular pathogen, and *M. tuberculosis* and *S. typhi*, which are both facultative intracellular pathogens. We believe that the information that is emerging from these studies will provide an insight into the general features shared by all microorganisms that have adapted to persist in the face of a highly evolved host immune system.

#### Persistent mycobacterial infections

Pathogenic mycobacteria cause several long-term infections in their respective hosts. *M. tuberculosis* causes tuberculosis (TB), one of the oldest known human infectious diseases, and this bacterium is estimated to infect one-third of the global population<sup>8</sup>. Primary infection with *M. tuberculosis* involves replication of the organism at the initial pulmonary site of infection. This is followed by bacillaemia, in which small numbers of bacteria are disseminated to the extrapulmonary organs — such as the regional lymph nodes — as well as to uninfected portions of the lung, by a mechanism that may involve the migration of *M. tuberculosis* within DENDRITIC CELLS<sup>9,10</sup>. Adaptive immunity and restriction of bacterial growth occurs after this dissemination and is probably promoted by the arrival of bacteria in extrapulmonary lymphoid organs<sup>4,11</sup>.

Most individuals resolve infection with *M. tuberculosis* soon after the onset of adaptive immunity<sup>12</sup>. However, in some infected individuals, the organisms are never completely cleared by the immune response<sup>4</sup>. Persistently infected individuals can harbour bacteria for many years, and even throughout their life. Infected individuals are at risk of experiencing the conversion of an asymptomatic infection into a highly contagious, clinically active and potentially deadly disease state that is known as reactivation TB. The risk of conversion from an asymptomatic infection to one that is clinically active is greatest soon after the initial infection, and this occurs most often in immunologically compromised individuals, such as newborns, the elderly and those who are infected with HIV<sup>13,14</sup>.

#### Mycobacterial survival at the immune interface

*Persistent mycobacteria reside in granulomas.* Although the exact location of viable latent mycobacteria during persistent infections remains controversial, bacteria are often found inside macrophages within granulomas, which are formed in response to persistent intracellular pathogens<sup>15</sup> (FIG. 1). Tuberculous granulomas in humans and mice contain an organized collection of differentiated macrophages, T lymphocytes, some B lymphocytes, dendritic cells, neutrophils, fibroblasts and extracellular matrix components<sup>16,17</sup>. Granulomas are thought to arise initially from aggregates of mononuclear phagocytes that surround individual infected macrophages. These macrophages become activated, and in many cases several macrophages fuse to form giant cells, which are also formed in response to other persistent

#### RETICULOENDOTHELIAL SYSTEM

A diffuse system of cells that helps the body fight infection and eliminate cellular debris through the action of phagocytic cells (such as macrophages), Kupffer cells in the liver and reticular cells of the spleen, bone marrow and lymph nodes.

#### MACROPHAGES

Cells of the mononuclear-phagocyte system that can phagocytose foreign particulate material. Macrophages are present in many tissues and are important for nonspecific immune reactions.

#### DENDRITIC CELLS

Professional antigen-presenting cells that take up proteins and present peptide antigens to T cells in conjunction with accessory molecules that stimulate T-cell activation. They are characterized by many long, thin processes extending from the cell body.

Table 1 | **Some persistent bacterial pathogens of humans**

Pathogen	Disease conditions	Likely sites of persistence
<i>Mycobacterium tuberculosis</i>	Tuberculosis	Macrophages in various sites and in granulomas
<i>Salmonella enterica</i> serovar Typhi	Typhoid fever	Macrophages in bone marrow, the RES and possibly the gall bladder
<i>Chlamydia</i> spp.	<i>C. pneumonia</i> causes respiratory and cardiovascular disease; <i>C. trachomatis</i> causes trachoma, genital-tract infections and lymphogranuloma venereum	Epithelial and endothelial cells
<i>Helicobacter pylori</i>	Gastritis; ulcers; gastric cancer; MALT lymphoma	Extracellular; possibly also intracellular in the stomach
<i>Brucella</i> spp.	Brucellosis (this can be chronic, leading to lymphadenopathy and hepatosplenomegaly)	Macrophages in the RES
<i>Borrelia burgdorferi</i>	Lyme disease	Disseminated in various organs
<i>Bartonella henselae</i>	Cat-scratch disease; bacillary angiomatosis; bacillary peliosis hepatitis	Extracellular; in erythrocytes in blood
<i>Neisseria gonorrhoea</i>	Genital-tract infections, which can lead to epididymitis, pelvic inflammatory disease and infertility	Extracellular; intracellular at mucosal sites
<i>Neisseria meningitidis</i>	Invasive infection results in meningitis	Nasopharynx; NALT?
<i>Streptococcus pneumoniae</i>	Acute otitis media; bacteraemia; meningitis	Nasopharynx; NALT?
<i>Streptococcus pyogenes</i>	Acute pharyngotonsillitis; pneumonia; endocarditis; skin, soft tissue and bone infections (necrotizing fasciitis)	Nasopharynx; NALT?
<i>Haemophilus influenzae</i> type B	Pneumonia; meningitis; bacteraemia	Nasopharynx; NALT?

NALT, nasopharyngeal-associated lymphatic tissue; RES, reticuloendothelial system.

infections, particularly those caused by viruses<sup>15</sup>. T lymphocytes and other immune cells are recruited early during the process of granuloma formation<sup>18</sup>. The lesion that is formed is sealed off from surrounding tissue by epithelioid cells, which have tightly interdigitated cell membranes that form zipper-like arrays and link adjacent cells, and which can also be fibrotic and calcified. In the centre of granulomas there is usually an area of caseous necrosis — a region of cellular debris that has a distinct appearance.

How does *M. tuberculosis* survive within these lesions for so many years? One hypothesis is that persistent bacteria are either in a non-replicative state or only have low levels of replication within the amorphous debris at the caseous centre of the granuloma<sup>19</sup>. Evidence in humans that the persisting bacteria are in a dormant state comes from the results of culturing and staining diseased tissues from patients who have undergone chemotherapy, which might have resulted in false-negative culturing results<sup>19–21</sup>. An alternative hypothesis as to how a constant bacterial load is maintained is that there is a balance between active bacterial replication and killing by the immune system. This is an active area of research and is discussed in more detail below.

**Survival within macrophages.** Pathogenic mycobacteria initiate long-term infection by entering host macrophages<sup>22</sup>, after which they cause extensive remodelling of the PHAGOSOMAL environment to prevent the normal maturation of this organelle into an acidic, hydrolytic compartment<sup>23</sup>. The ability of pathogenic mycobacteria to replicate and/or survive in macrophages has an essential


role in persistence *in vivo*, and is a feature that distinguishes pathogenic from non-pathogenic strains<sup>22</sup>.

As infected macrophages are the main reservoir of infection by pathogenic mycobacteria, studies of the biology and biogenesis of the mycobacteria-containing phagosome have generated information that is important for the understanding of the cell biology, immunology and microbiology of these pathogens<sup>23</sup>. Many groups have described the trafficking of mycobacteria within unactivated macrophages in tissue-culture experiments. In brief, mycobacteria interfere with phagosome maturation by blocking the fusion of nascent phagosomes with endosomal and lysosomal compartments and by causing alterations in membrane proteins that normally promote the formation of an acidic phagolysosome. The steps involved in this process are beyond the scope of this review, but are described in detail in REF 24

In addition to the ability to block phagosome maturation in some circumstances, pathogenic mycobacteria have also evolved mechanisms that allow them to persist in macrophage phagolysosomes, within granulomas, in the presence of a host immune response. A recent study indicated that within frog granulomas ~60% of intact bacteria of the species *Mycobacterium marinum* — which is closely related to *M. tuberculosis* — resided in phagolysosomes, and the level of phagolysosomal fusion correlated with the level of macrophage activation<sup>25</sup>. Therefore, it is possible that mycobacteria have at least two mechanisms of adaptation to intramacrophage survival: restriction of phagolysosomal fusion early in infection and adaptation to phagolysosomal fusion within the activated macrophages of granulomas later

#### PHAGOSOME

A membrane-bound, cytoplasmic vacuole formed around particles that are ingested by phagocytosis.



**Figure 1 | Persistent mycobacterial infection and the host immune response. a** | Pathogenic mycobacteria use several receptors to enter macrophages, where they reside in a unique vacuole. The amount of mycobacterial replication is controlled by many host immune factors. Effector T cells (including CD4<sup>+</sup> and CD8<sup>+</sup> T cells and double-negative (DN) T cells) and macrophages participate in the control of infection. Interferon- $\gamma$  (IFN- $\gamma$ ) and tumour-necrosis factor- $\alpha$  (TNF- $\alpha$ ) produced by T cells are important macrophage activators. Macrophage activation promotes phagosomal maturation, vacuole acidification and the production of antimicrobial molecules, such as reactive nitrogen intermediates (RNIs) by nitric oxide synthase 2 (NOS2), reactive oxygen intermediates (ROIs), antimicrobial peptides and the NOS2-independent 47-kDa guanosine triphosphatase protein LRG-47, which can block bacterial replication. The production of the proinflammatory cytokines TNF- $\alpha$ , interleukin (IL)-18 and IL-23 by activated macrophages also contributes to controlling the intracellular replication of mycobacteria. The ability of mycobacteria to inhibit the secretion of IL-12 by infected macrophages might contribute to bacterial survival, as this cytokine normally functions to induce the production of IFN- $\gamma$ . **b** | In most persistent mycobacterial infections, the bacteria are initially contained in granulomas. Tuberculous granulomas are thought to arise from aggregates of phagocytic cells that surround individual infected macrophages. These structures contain many T and B lymphocytes, dendritic cells, neutrophils, fibroblasts and extracellular matrix components (for simplicity, only T cells are shown here). Another striking feature of certain tuberculous granulomas is the presence of caseous necrosis in the centre of the granuloma. Some of the genes that are specifically expressed by mycobacteria in granulomas encode the following proteins: isocitrate lyase (ICL)<sup>60</sup>, an enzyme essential for the metabolism of fatty acids; outer-membrane proteins of the PE/PGRS family that might have a role in antigenic variation; the transcriptional regulator MprA, which is involved in the regulation of unidentified genes during adaptations that are required for persistence<sup>61</sup>; and PcaA, which encodes a cyclopropane synthase. Mycobacteria that lack PcaA have reduced levels of persistence in the chronic mouse model<sup>63</sup>.

## Box 2 | Insights into host–pathogen interactions gained from genetics

Host genetic factors strongly determine the outcome of infectious disease. However, the molecular mechanisms of resistance and susceptibility in humans are only just beginning to be investigated. Mouse models of human infectious disease have been used to identify and map host loci that are involved in controlling the complex aspects of host–pathogen interactions (for recent reviews, see REFS 128,219). Three main approaches have been taken to identify these loci: production of mouse mutants by gene targeting; positional cloning of host-resistance genes in mutant mice; and mapping and characterization of quantitative trait loci (QTL) that control the complex aspects of host–pathogen interactions.

In some cases, the results of knockout-mouse studies have provided important information about the genetic basis of susceptibility to bacterial infections in humans (TABLE 2). For example, mice with null mutations in the genes encoding interferon- $\gamma$  (IFN- $\gamma$ ) and either of the subunits of the IFN- $\gamma$  receptor have been shown to be susceptible to infection with pathogens such as *Listeria monocytogenes*, *Salmonella enterica* serovar Typhimurium and *Mycobacterium tuberculosis*, among others<sup>219,220</sup>. The investigation of a paediatric syndrome — known as idiopathic mycobacterial infection or Mendelian susceptibility to mycobacterial infection — led to the identification of various human mutations in the genes encoding the IFN- $\gamma$  receptor, interleukin-12 (IL-12) and the IL-12 receptor. These mutations lead to deficiencies that abrogate IFN- $\gamma$ -mediated and IL-12-mediated immunity. The phenotype of patients with this syndrome is an increase in the occurrence and severity of infections with mycobacteria that are usually poorly pathogenic, such as the bacille Calmette–Guérin strain, and non-typhoidal salmonella, such as *Salmonella enteritidis*. IFN- $\gamma$  and IL-12 are therefore indispensable for bactericidal granuloma formation and protective immunity against mycobacteria and salmonella in mice and humans. By contrast, *Helicobacter pylori* does not seem to cause invasive or more severe disease in immunocompromised or very young individuals. For example, IFN- $\gamma$ -knockout mice are colonized with higher numbers of *H. pylori* during the first 4 weeks post-infection, but the mice survive. Indeed, persistent *H. pylori* infection of IFN- $\gamma$ -knockout mice resulted in less gastric inflammation even in the presence of high levels of bacteria. So, IFN- $\gamma$  and other pro-inflammatory cytokines (TABLE 2), which are ordinarily necessary for controlling bacterial infections, might actually contribute to the histological changes that are associated with *H. pylori* infection, such as atrophic gastritis, intestinal metaplasia and dysplasia — conditions that can lead to the development of *H. pylori*-induced gastric cancer.

in infection. It is still unclear how the bacteria sense these different intramacrophage environments; the identification of the bacterial effector proteins that are involved in this should provide considerable insight into this crucial stage of mycobacterial pathogenesis.

In further support of the proposal that mycobacteria use different strategies according to the circumstances, recent publications indicate that mycobacteria have temporal and immune-response-triggered differences in gene expression both in activated macrophages *in vitro* and in macrophages isolated from infected tissue<sup>26–31</sup>. In addition, a recent study showed differential mycobacterial survival in type 1 (interleukin-23 (IL-23)-producing) and type 2 (IL-10-producing) macrophages<sup>32</sup>. The immune status of the macrophage therefore has an important role in bacterial persistence. Indeed, the control of bacterial growth in murine models of latency requires interferon- $\gamma$  (IFN- $\gamma$ ), tumour-necrosis factor- $\alpha$  (TNF- $\alpha$ ) and nitric oxide (NO)<sup>16</sup>, all of which can alter the environment of the bacteria-containing phagosome and lead to killing of the pathogen.

IFN- $\gamma$  is a crucial component of immunity to TB as it activates infected host macrophages, which directly inhibit the replication of *M. tuberculosis*. The importance of this molecule in the control of mycobacterial infections is highlighted by the discovery of IFN- $\gamma$ -related genetic mutations that predispose affected individuals to active TB, as well as to other infections that are caused by intracellular bacterial species, such as *Salmonella* spp.<sup>33</sup> (BOX 2; TABLE 2). IFN- $\gamma$  induces the expression of NO synthase 2 (NOS2) and of the newly identified, NOS2-independent, 47-kDa guanosine triphosphatase protein LRG-47, and both pathways are

important in controlling intracellular *M. tuberculosis* replication<sup>34–37</sup>. However, a proportion of the bacteria are clearly still able to survive in macrophages, perhaps by a mechanism that involves inhibiting STAT1-mediated IFN- $\gamma$  transcriptional responses<sup>38</sup> and/or suppressing the secretion of IL-12 — a proinflammatory CYTOKINE that acts to amplify IFN- $\gamma$  production<sup>39,40</sup> — which may in part be mediated by the *M. tuberculosis* Snm secretion pathway<sup>41</sup>. It is also likely that the ability to resist killing by antimicrobial peptides contributes to mycobacterial survival in macrophages<sup>42</sup>.

#### Animal models of mycobacterial persistence

From both a therapeutic and an epidemiological viewpoint, the study of persistent mycobacterial infections in animal models is very important given the difficulties of studying latent TB in humans. Some research has been done using guinea pigs, which are able to arrest the initial acute phase of bacterial replication during *M. tuberculosis* infection<sup>43</sup>. However, although the resulting pathology resembles that seen in human disease, these animals succumb to the pathological consequences of infection<sup>43</sup>. Persistent infection can also occur after intratracheal infection of cynomolgus monkeys<sup>44,45</sup>. Although it is likely that this closely mimics human infections, high costs limit the widespread use of this non-human primate model. Therefore, many research groups commonly use mouse models of *M. tuberculosis* infection or frog and fish models of *M. marinum* infection. Although much information can be gained from these models, care should be taken in extrapolating the results obtained with these models directly to human TB.

#### CYTOKINES

Low-molecular-weight proteins that are important for immunity, inflammation and development, and which contribute to the pathophysiology of acute and chronic infections.

Table 2 | **Genes involved in susceptibility to *M. tuberculosis*, *Salmonella* serotypes and *H. pylori***

Gene product	Phenotype in knockout mice*	Phenotype in humans	References
<b><i>Mycobacterium tuberculosis</i></b>			
TNF- $\alpha$ p55 receptor	High susceptibility; increased granuloma necrosis	U	75
TNF- $\alpha$	High susceptibility; increased granuloma necrosis	U	75
IFN- $\gamma$	High susceptibility; increased granuloma necrosis	I	128,221,222
IL-12 (p40)	High susceptibility; defective granuloma formation	I	128,223,224
IL-12R $\beta$ 1	High susceptibility	I	225–227
IL1 $\alpha/\beta$	Moderate susceptibility; larger granulomas, but no necrosis	U	228
IL-18	Moderate susceptibility; larger granulomas in lungs	U	229
NOS2	High susceptibility; necrotic granulomatous pneumonitis	U	35
NRAMP1	High susceptibility associated with mice homozygous for the Nramp1D169/D169 allele	I	94
TRL3	Increased resistance	U	230
TRL4	Increased resistance	U	230
<b><i>Salmonella</i> serotypes</b>			
NF-IL6	High susceptibility; impaired macrophage killing of bacteria	U	231
TNF- $\alpha$ p55 receptor	Higher susceptibility; reduced clearance of bacteria from spleen and liver	U	232
IFN- $\gamma$	High susceptibility	I	233
IL-12 (p40)	–	I	128
IL-12R $\beta$ 1	–	I	128
LPS-binding protein	High susceptibility	U	234
NOS2	High susceptibility; increased bacterial replication in early phase of infection	U	235
NRAMP1	High susceptibility associated with mice homozygous for the Nramp1D169/D169 allele	U	94
<b><i>Helicobacter pylori</i></b>			
IFN- $\gamma$	Higher numbers of bacteria early in infection; no inflammation in persistently infected mice	U	236
IL-1 $\beta$	–	Cancer <sup>†</sup>	237
IL-1 $\beta$ receptor	–	Cancer <sup>†</sup>	238
TNF- $\alpha$	–	Cancer <sup>†</sup>	239
IL-10	More severe gastritis followed by bacterial clearance	Cancer <sup>§</sup>	116, 239

\*The phenotype listed for mice is for experimental infections with virulent bacteria. <sup>†</sup>Human polymorphisms that are associated with higher levels of expression have been linked to an increased risk of gastric cancer and its precursors. <sup>§</sup>Human polymorphisms that reduce expression of the anti-inflammatory cytokine IL-10 are associated with increased risk of distal gastric cancer. I, proven susceptibility in humans where normal individuals do not become infected with *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium bovis* bacille Calmette–Guérin, *Mycobacterium smegmatis*, *Mycobacterium intracellulare*, other non-pathogenic mycobacterial strains, *Salmonella enterica* serovar Typhimurium, *Salmonella enteritidis*, *Salmonella enterica* serovar Paratyphi, and group B *Salmonella*. U, unknown or no proven susceptibility in humans. IFN- $\gamma$ , interferon- $\gamma$ ; IL, interleukin; IL-12R $\beta$ 1, IL-12 receptor  $\beta$ 1; LPS, lipopolysaccharide; NF-IL6, nuclear protein IL6; NOS2, nitric oxide synthase 2; TRL, tuberculosis-resistance locus; TNF- $\alpha$ , tumour-necrosis factor- $\alpha$ .

**Mouse models of *M. tuberculosis* infection.** Several mouse models of TB latency have been established<sup>46–48</sup>. The Cornell mouse model (also known as the drug-induced model) involves partial clearance of *M. tuberculosis* infection by incomplete chemotherapy; the infection is reduced to a point at which no bacterial colonies are recovered<sup>46</sup>. Drug intervention is needed to induce the latent state, which is not necessary in human disease. The low-dose mouse model of latent TB (also known as the chronic or plateau model) involves aerosol infection or infection by intravenous routes. This results in an initial acute phase of bacterial replication that is controlled by the onset of an adaptive immune

response, followed by a stable maintenance at high levels in the lung over many months. The mice seem healthy until the disease reactivates, which can take place as much as 18 months later<sup>48</sup>. This chronic model resembles latency in humans in that it depends on the host immune response to contain the infection. However, unlike latent TB in humans, this model results in large numbers of bacteria, which leads to pulmonary damage that steadily accumulates in the lungs of chronically infected animals<sup>49</sup>.

Although these mouse models have limitations, several groups have used them to address the metabolic state of persistent mycobacteria. Rees and Hart

compared total microscopic counts of bacteria in lungs from infected mice with counts of viable bacteria over a period of several months<sup>30</sup>. The number of bacteria obtained by both techniques remained constant. One interpretation of these findings is that the bacteria were replicating either very slowly or not at all. However, it is possible that any difference between the total number of bacteria visualized and the number of viable bacteria was not within the limits of detection of the methods used.

More recently, other groups have used mouse models to compare bacterial gene expression under *in vitro* conditions that induce a non-replicating or dormant bacterial state (that is, conditions of nutrient deprivation<sup>51</sup> and oxygen depletion<sup>52</sup>) with *in vivo* bacterial gene expression. These studies used either quantitative real-time PCR (qRT-PCR) or cDNA microarray techniques<sup>26,27,30</sup>. One such study of *M. tuberculosis* gene expression in infected mice showed that  $\alpha$ -CRYSTALLIN and genes of the DosR regulon are highly expressed in response to host immunity mediated by type 1 HELPER T CELLS (T<sub>H</sub>1 cells)<sup>27</sup>. DosR seems to have a crucial role in mediating the expression of a series of hypoxia-induced and NO-induced *M. tuberculosis* genes<sup>53–55</sup> — a transcription pattern that is characteristic of the non-replicating persistence that is associated with the adaptation of tubercle bacilli to hypoxia *in vitro*<sup>52</sup>. It was inferred from this study that host immunity induces the arrest of bacterial growth<sup>27</sup>.

More recently, qRT-PCR has been used to measure the levels of selected *M. tuberculosis* mRNAs during laboratory culture, *in vivo* in the lungs of mice and in lung tissue from four chronically infected humans<sup>26</sup>. In culture, the differential expression of *M. tuberculosis* mRNAs that are associated with iron limitation, alternative carbon metabolism and cellular hypoxia — conditions that are thought to occur in granulomatous lesions associated with TB — correlated with those that were seen in bacteria isolated from wild-type mice. However, in bacteria isolated from human TB lung specimens, this set of mRNAs did not show the same expression patterns as those seen in mice. This might reflect host-specific differences or the fact that the human lung tissue was not microdissected, resulting in mixed bacterial populations from different environments. The latter hypothesis is supported by a recent study that used DNA microarrays to examine genome-wide expression profiles of *M. tuberculosis* isolated from human lung tissue that was surgically removed from patients who had not been treated with antibiotics, but were infected with high levels of bacteria. The gene-expression profiles of *M. tuberculosis* were shown to be characteristic of the site of infection (caseous centres of granulomas, pericavities or distant lung), indicating that *M. tuberculosis* actively senses and responds to its microenvironment (H. Rachman and S. H. E. Kaufmann, personal communication).

**Frog and fish models of *M. marinum* infection.** Other animal models have been developed more recently that use *M. marinum*, which causes a TB-like disease in ectothermic hosts such as frogs and fish and is a useful

model system to study mycobacterial pathogenesis<sup>22</sup>. Experiments using the *M. marinum* model have indicated that persistent mycobacteria are in a metabolically and replicatively active state. Bouley *et al.* have shown by transmission electron microscopy in conjunction with immunohistochemistry and acid phosphatase cytochemistry that even long-term, single granulomas are surprisingly dynamic environments, within which bacterial replication and phagocytic killing occur simultaneously<sup>25</sup>. In support of this, using the attenuated BACILLE CALMETTE–GUÉRIN strain in rabbits, Dannenberg and colleagues arrived at a similar conclusion<sup>56</sup>. These data indicate that mycobacteria are not in an inert or ‘spore-like’ state, and that relatively constant bacterial numbers are maintained in the presence of an active immune response. Furthermore, studies using DIFFERENTIAL FLUORESCENCE INDUCTION to analyse *M. marinum* gene expression in granulomas showed that most of the promoters that were found to be induced drive the expression of genes that encode proteins with metabolic and synthetic functions and that are expressed during logarithmic-phase growth in laboratory media<sup>57</sup>. These results indicate that persistent mycobacteria are metabolically active; however, they do not prove that they are actively dividing. Furthermore, these studies were performed using the relatively stable reporter green fluorescent protein (GFP), so that downregulation of bacterial gene expression within granulomas might not have been detected. It is therefore possible that persisting bacteria exist as a mixed population, in which some are actively replicating and others are in an inactive state.

### Mycobacterial persistence factors

In recent years, our understanding of mycobacterial pathogenesis has advanced rapidly. Many genes that are important for pathogenesis have been identified in virulence expression screens and mutant screens, and this work has been reviewed recently<sup>22</sup>. Saseti *et al.* have combined mutagenesis using the mariner transposon with microarray technology to determine the genes that are required for mycobacterial growth under certain *in vitro* conditions (a method called TraSH, for transposon site hybridization)<sup>58</sup>. When this method was applied to a mouse model of infection, several genes were found to be required at different stages after infection<sup>59</sup>. One class of mutants — known as persistence mutants — are able to establish an infection to the same level as wild-type bacteria, but are unable to maintain levels of bacteria in the lungs to the same extent as wild-type strains.

The further characterization of these persistence mutants awaits further studies. However, a number of *M. tuberculosis* genes have previously been indicated to be important for persistent infection in the chronic mouse model on the basis of gene-expression studies and experiments using bacteria carrying knockout mutations (reviewed in REF. 5). Most notably, the results of McKinney *et al.* show that persistence in mice is facilitated by isocitrate lyase (ICL)<sup>60</sup>, an enzyme that is essential for the metabolism of fatty acids. Disruption of the *icl* gene attenuated bacterial persistence and virulence in immunocompetent mice, without affecting bacterial

#### $\alpha$ -CRYSTALLIN

The expression of this chaperonin protein is upregulated *in vitro* by hypoxia.

#### HELPER T CELLS

A subpopulation of activated CD4<sup>+</sup> T cells that secrete characteristic cytokines and function primarily in cell-mediated responses by promoting the activation of cytotoxic T cells and macrophages.

#### BACILLE CALMETTE–GUÉRIN

The attenuated *Mycobacterium bovis* live vaccine.

#### DIFFERENTIAL FLUORESCENCE INDUCTION

A selection strategy used to identify bacterial genes that are preferentially expressed when a bacterium is in a particular environment. By inserting random pieces of bacterial DNA in front of a promoterless green fluorescent protein (GFP) gene, flow cytometry can be used to screen for genes expressed in specific environments.

growth during the acute phase of infection. These data indicate that during late stages of infection, *M. tuberculosis* cells might convert lipids into carbohydrates through the GLYOXYLATE-SHUNT PATHWAY<sup>60</sup> and that latent bacteria might reside in an environment such as lung granulomas, in which carbohydrates are limited but lipids are available.

Several other persistence mutants have been identified. One of these affects the transcriptional regulator MprA, which is involved in the regulation of unidentified genes during adaptive responses that are required for persistence<sup>61</sup>. In addition, several mutants have been identified that have alterations in their cell walls<sup>62</sup>. For example, the *M. tuberculosis pcaA* mutant (*pcaA* encodes a cyclopropane synthase) shows reduced levels of persistence in the chronic mouse model<sup>63</sup>. The roles of these bacterial genes in persistent infections and their functions in immune modulation await further studies.

#### Immune responses to persistent mycobacteria

Substantial progress has been made in understanding the immune-system mechanisms that are involved in the containment of the initial phase of *M. tuberculosis* infection (reviewed recently in REFS 4,5,16). However, less is known about the immune mechanisms that are involved during persistent mycobacterial infections. In addition to reactivation, recent work using molecular-fingerprinting techniques has documented the reinfection of immunocompetent individuals with new strains of *M. tuberculosis*<sup>22</sup>. These data show that immunity to TB can be incomplete, and indicate that reinfection, at least in areas where TB is prevalent, probably has a greater role than was previously appreciated.

Indeed, the dynamic nature of mycobacteria and their interactions with granulomas during persistent infection is highlighted by the recent findings of Cosma *et al.* This group showed that exogenously infecting *M. marinum* in zebrafish rapidly enter pre-existing granulomas by specific mycobacteria-mediated mechanisms that direct infected macrophages into granulomas<sup>64</sup> (FIG. 1). To probe the cellular dynamics of mycobacterial reinfection *in vivo*, Cosma and colleagues followed the route of superinfecting *M. marinum* or an unrelated *Salmonella* strain — which were labelled with macrophage-inducible GFP reporter constructs — in the context of a previously established infection. The superinfecting *M. marinum* — and not the *Salmonella* strain — trafficked into pre-existing granulomas, rapidly expressed granuloma-specific promoters and remained in these lesions for up to 2 months<sup>64</sup>. These findings indicate that mycobacteria rapidly adapt to the mature granuloma environment and provide new insights into the interactions of these bacteria with the adaptive immune system.

The role of the adaptive immune response in persistent mycobacterial infections is an area of great interest. There is some evidence that CD8<sup>+</sup> T cells secrete most of the IFN- $\gamma$  that is produced during persistent infection in the chronic mouse model. This is in contrast to the acute phase of disease, during which CD4<sup>+</sup> T cells produce most of the IFN- $\gamma$ <sup>65,66</sup>, indicating a differential activation

of T-cell subsets in these two phases of infection<sup>4</sup>. Whether or not this is the case, CD4<sup>+</sup> T cells have an important but as yet undefined role in the control of persistent infection<sup>67</sup>. Although other activities of CD8<sup>+</sup> T cells, in addition to IFN- $\gamma$  production, might also be important for the control of persistent infections<sup>68–70</sup>, further studies are needed to determine the exact roles of these cells.

The production of immunosuppressive cytokines — such as IL-10 and transforming growth factor- $\beta$  (TGF- $\beta$ ) — has been documented in humans with active TB<sup>71–73</sup>, and IL-10 production is increased in the lungs of mice that show chronic mycobacterial infection. This indicates that the ability of IL-10 to downregulate the immune response might contribute to the reactivation of chronic *M. tuberculosis* infection<sup>74</sup>. In animal models, the proinflammatory cytokine TNF- $\alpha$  has a key role in host responses against TB<sup>75,76</sup>, including granuloma formation and the containment of disease<sup>18,77</sup>. Furthermore, treatments with antibodies that neutralize TNF- $\alpha$  cause reactivation of TB in a mouse model of latent infection<sup>78</sup> and in human latent infection, as shown by the clinical observation of reactivation of TB during the treatment of autoimmune disease<sup>79</sup>. TNF- $\alpha$  therefore has a significant role in the control of persistent *M. tuberculosis* infections and, as discussed below, is equally important in persistent *Salmonella* infections.

#### Persistent *Salmonella* infections


*Salmonella* serovars are responsible for human diseases ranging from gastroenteritis to systemic infections. Systemic *Salmonella* infection is usually host-dependent, and *S. typhi* causes only systemic infection — typhoid fever — in humans. *Salmonella enterica* serovar Typhimurium (*S. typhimurium*) infection of mice and *S. typhi* infection of humans is characterized by inflammation at the site of bacterial entry, which is typically at the PEYER'S PATCHES<sup>80</sup>. After *Salmonella* spp. penetrate the epithelial barrier, they preferentially infect phagocytes within the lamina propria (FIG. 2). In *Salmonella* gastroenteritis, the infection is usually self-limiting and does not proceed beyond the lamina propria. However, in host-adapted salmonellosis, such as typhoid fever, *Salmonella*-infected phagocytes gain access to the lymphatics and bloodstream, allowing the bacteria to spread to the liver and the spleen<sup>81</sup>, and can persist in the gall bladder and bone marrow<sup>82,83</sup>.

*S. typhi* and *Salmonella enterica* serovar Paratyphi (*S. paratyphi*) serovars are important human pathogens of immense concern to public health and with considerable economic impact. They are endemic in regions of the world where drinking-water quality and sewage-treatment facilities are poor<sup>1,84</sup> and infections remain difficult to treat by antibiotic therapy due to the increasing frequency of resistant bacteria<sup>85</sup>. A significant percentage (1–6%) of typhoid patients become chronic carriers of *S. typhi*, as do many people who have never had a clinical history of typhoid fever<sup>86–88</sup>. These individuals shed bacteria in their stools and urine for periods of time that range from a year to a lifetime, without any apparent signs of disease<sup>89</sup>. Typhoid carriers are of

**GLYOXYLATE-SHUNT PATHWAY**  
A biochemical pathway that is used by plants and microorganisms to metabolize acetate or long-chain fatty acids as a source of energy.

**PEYER'S PATCHES**  
Lymphoid nodules located in the small intestine that trap antigens from the gastrointestinal tract and provide sites where immune cells — such as B and T lymphocytes, macrophages and dendritic cells — can interact with antigen.





**Figure 2 | Persistent *Salmonella* infection.** Schematic representation of persistent infection with *Salmonella enterica* serovar Typhi in humans. Bacteria enter the Peyer's patches of the intestinal tract mucosal surface by invading M cells — specialized epithelial cells that take up and transcytose luminal antigens for uptake by phagocytic immune cells. This is followed by inflammation and phagocytosis of bacteria by neutrophils and macrophages and recruitment of T and B cells. In systemic salmonellosis, such as typhoid fever, *Salmonella* may target specific types of host cells, such as dendritic cells and/or macrophages that favour dissemination through the lymphatics and blood stream to the mesenteric lymph nodes (MLNs) and to deeper tissues. This then leads to transport to the spleen, bone marrow, liver and gall bladder. Bacteria can persist in the MLNs, bone marrow and gall bladder for life, and periodic reseeded of the mucosal surface via the bile ducts and/or the MLNs of the small intestine occur, and shedding can take place from the mucosal surface. Interferon- $\gamma$  (IFN- $\gamma$ ), which can be secreted by T cells, has a role in maintaining persistence by controlling intracellular *Salmonella* replication. Interleukin (IL)-12 — which can increase IFN- $\gamma$  production — and the proinflammatory cytokine tumour-necrosis factor- $\alpha$  (TNF- $\alpha$ ) also contribute to the control of persistent *Salmonella* (not shown).

special concern from a public-health viewpoint as they are the reservoirs for the spread of infection and disease. From the bacterial perspective, persistent infection is essential for microbial survival in nature. *S. typhi* is carried for years — even in the presence of an immune response — and chronic carriers of *S. typhi* have high levels of circulating serum antibodies to the Vi antigen and to flagellar antigens<sup>84,90</sup>. Investigating the chronic carrier state in salmonellosis should provide an insight into bacterial survival strategies, as well as information that could be used to develop new approaches for the treatment of typhoid and other persistent microbial infections.

#### Mouse models of *Salmonella* persistence

Mouse typhoid is similar to human typhoid in a number of ways, although different strains of mice have varying levels of susceptibility to *Salmonella* infection<sup>91</sup>. In mice, a significant component of innate resistance or susceptibility to infection with *S. typhimurium* is controlled by the gene *Nramp1* (also known as *Slc11a1*), which encodes a proton/divalent-cation antiporter that regulates susceptibility to infectious disease<sup>92</sup>. *Nramp1* expression is restricted to cells of the monocyte/macrophage lineage, and because it localizes to the vacuolar membrane it affects the capacity of the host to control intracellular replication of *Salmonella* bacteria — as well as

*Mycobacterium* spp. and *Leishmania* spp. — presumably by depriving the bacteria of divalent cations<sup>93</sup>. *Nramp1* is therefore involved in the control of the exponential growth of *S. typhimurium* in the reticuloendothelial organs during the early phase (first week) of infection in mice<sup>94</sup>. Consequently, mice carrying two copies of the mutant *Nramp1*<sup>Asp169</sup> allele are significantly less resistant to lethal *S. typhimurium* infections than mice that harbour the wild-type *Nramp1*<sup>Gly169</sup> allele<sup>94</sup>.

*Salmonella* clearance during the late phase of infection (3–4 weeks post-infection) seems to be influenced by various host loci through effects on the acquired immune response. The mouse MAJOR HISTOCOMPATIBILITY COMPLEX (MHC; also known as H2) has an important role in the clearance of *Salmonella*<sup>91,95</sup>. Similarly, in humans, a genetic link between specific class II and class III MHC haplotypes and relative resistance to *S. typhi* has been shown<sup>96</sup>. Several studies have also shown a requirement for both CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes for clearance of *Salmonella* infections<sup>97–100</sup>, and the humoral response is also required for this<sup>100–102</sup>.

Historically, *Salmonella* pathogenesis has been investigated in *Nramp1*<sup>Asp169</sup> mice, which are highly sensitive to *Salmonella* infection. This reflects, in part, the fact that death is an experimental endpoint that is readily measured, so this model is useful for assessing the relative contributions of *Salmonella* virulence factors and host

#### MAJOR HISTOCOMPATIBILITY COMPLEX

A complex of genes encoding cell-surface molecules that are required for antigen presentation to T cells.

immune responses in an acute infection. Although acute *S. typhimurium* infections have been well characterized using this model, it is not suitable for studies of long-term carriage, as the mice either die rapidly from relatively low doses of *Salmonella* or attain sterilizing immunity. Previous studies using specific *S. typhimurium* mutant strains — such as an attenuated strain that is unable to synthesize aromatic amino acids *de novo* (*aroA*<sup>-</sup> strain) or a mutant in polynucleotide phosphorylase (PNPase) that has altered virulence gene expression — in *Nramp1*-deficient strains of mice have shown that these bacterial mutants can colonize mice for as long as 2 months<sup>103–105</sup>. Although these models are useful for understanding the development of protective immunity to *Salmonella*, they have not added a great deal to the understanding of the biology and pathogenesis of natural persistent *Salmonella* infections with wild-type bacteria.

Persistent *Salmonella* infection can be effectively studied using the 129sv mouse strain — which carries a wild-type *Nramp1* allele — and wild-type *S. typhimurium*. Oral infection of 129sv mice results in systemic infection that, in most cases, does not lead to death of the host. Persistent infection in this model is characterized by sporadic excretion of bacteria in stools and long-term carriage of *S. typhimurium* in low numbers within classical granulomatous lesions, which arise in the spleen, liver, gall bladder and mesenteric lymph nodes (MLNs)<sup>106</sup>. The data obtained from studies using persistently infected mice indicate that the most common site of chronic carriage of *S. typhimurium* is the MLNs<sup>106</sup>. Indeed, this is often the only site from which viable *Salmonella* can be recovered.

Chronic infections with *S. typhi* and *Salmonella enterica* serovar Dublin are classically associated with long-term excretion of bacteria and localization in the gall bladder<sup>107–109</sup>. Although humans that carry *Salmonella* chronically often have BILIARY-TRACT disease, this condition is not an absolute requirement for development of the carrier state<sup>88,110</sup>. A previous study showed that *S. typhi* was carried exclusively in MLNs 50 days after oral infection of chimpanzees<sup>111</sup>. In the case of *Salmonella enterica* serovar Pullorum, it was recently shown that bacteria are carried in the spleen and reproductive tract, specifically in the ovaries and oviducts of hens<sup>112</sup>. In a recent study from our own laboratory, we found the main site of chronic carriage of *S. typhimurium* in mice to be the MLNs, and not the gall bladder<sup>106</sup>. These studies indicate that the true reservoir of persistent bacterial carriage might change in response to the host immune status and the underlying disease, a situation that might also apply to human infections.

#### Persistent *Salmonella* in macrophages

The ability of *Salmonella* to survive in macrophages is required for systemic colonization of the host. Indeed, chronically infected humans and mice harbour *Salmonella* within the reticuloendothelial system for long periods of time, and our group has shown that the persistent bacteria reside in low numbers within MOMA2<sup>+</sup> MACROPHAGES residing in the MLNs<sup>106</sup>. The intracellular

trafficking of the *Salmonella* phagosome has been analysed in unactivated tissue-culture macrophages and it has been concluded that most *Salmonella*-containing vacuoles do not interact extensively with late endosomes and lysosomes<sup>113</sup>. Studies of intracellular *Salmonella* gene expression in unactivated macrophages have shown that numerous virulence and SOS-response genes show significant changes in expression in response to the vacuolar environment<sup>114</sup>. However, the trafficking and gene expression patterns of persistent intracellular *Salmonella* have not yet been investigated. Furthermore, the fate of macrophages that are persistently infected with *Salmonella* is not known, nor is it clear how the bacteria infect new host cells over time. It is possible that bacteria persist within macrophages for the lifetime of the host cell and then infect a new macrophage. However, *S. typhimurium* is able to induce host-cell death *in vivo*<sup>115,116</sup>, providing a potential mechanism by which *Salmonella* can escape from an infected cell to infect neighbouring cells. *S. typhimurium* mediates macrophage death by at least two mechanisms. One mechanism involves rapid macrophage death that requires the type III secretion system (TTSS) that is encoded by the *Salmonella* PATHOGENICITY ISLAND SPI1 (REF. 117). The potential role of SPI1 and SPI1-mediated macrophage cytotoxicity in persistent *S. typhimurium* infections is under investigation.

*S. typhimurium* can also induce macrophage death that occurs approximately 18 hours after infection. This delayed macrophage death requires another TTSS that is encoded by a second pathogenicity island, SPI2, and is used inside host cells<sup>118,119</sup>. It is possible that dead or dying macrophages containing *S. typhimurium* are phagocytosed by other macrophages that are recruited to the site of infection, which then serve as a safe haven in which *Salmonella* can survive while avoiding extracellular host defences. It is also possible that the SPI2-mediated mechanism of cell death is not active during persistent infection of macrophages. Indeed, differential expression of SPI genes could be a strategy used by persistent *Salmonella*<sup>120</sup>. It is clear that SPI2 is required to avoid the effects of PHAGOCYTTIC OXIDASE (PHOX) during infection of macrophages<sup>121</sup> and to initiate systemic infection<sup>122,123</sup>, but its role and the role of individual SPI2-secreted effector molecules in the continuing presence of persistent of *S. typhimurium* is not yet known.

#### Persistent *Salmonella* and the immune response

Mice that are persistently infected with *S. typhimurium* have high anti-*Salmonella* antibody titres<sup>106</sup>. This might represent a deliberate infection-associated shift from a T<sub>H</sub>1 to a T<sub>H</sub>2 response, which might be involved in keeping the numbers of bacteria inside each macrophage lower in the persistent *S. typhimurium* model than those reported in previous studies of acute infections in *Nramp1*-susceptible mice in which the mice died<sup>124</sup>. However, the adaptive immune response also provides positive feedback to the innate immune system through the synthesis of cytokines that either increase effector-cell numbers or activate these cells to produce an increased antibacterial response.

#### BILIARY TRACT

Includes the gall bladder and bile ducts, which make and transport bile. Bile contains salts or detergents that disrupt bacterial membranes; it also activates autolysins that digest peptidoglycan.

#### MOMA2<sup>+</sup> MACROPHAGES

MOMA2 is expressed in the cytoplasm of monocytes and macrophages. MOMA2<sup>+</sup> macrophages can be found in the splenic red pulp, in the cortex of the thymus, in the subcapsule and medullary regions of lymph nodes and in sites of acute and chronic inflammation.

#### PATHOGENICITY ISLANDS

Large (10–50-kb) insertions in the bacterial chromosome that encode virulence determinants. They are thought to be acquired by horizontal transfer.

#### PHAGOCYTTIC OXIDASE (PHOX)

Production of reactive oxygen intermediates, which can kill bacteria directly or after reacting with chlorine, is mediated by the NADPH oxidase system located in the membrane of the macrophage and includes the PHOX enzyme.

Table 3 | *Helicobacter pylori* virulence determinants

Virulence determinant	Description/potential role in pathogenesis	References
VacA	95-kDa secreted vacuolating toxin; induces apoptosis; involved in immunomodulation and colonization of mouse stomach	160–163,240
Cag-PAI	37-kb genomic fragment; contains 29 genes that encode a type IV secretion apparatus	241
CagA	120-kD protein; translocated into host cell by type IV secretion apparatus encoded on Cag-PAI; phosphorylated in host cell and binds SHP-2 tyrosine phosphatase; disrupts tight junctions; epidemiologic link to cancer	242–245
BabA	78-kDa outer membrane protein; binds to fucosylated Lewis B blood group antigen; mediates adhesion to epithelial cells and possibly stomach epithelium	188,246
Urease	Resists acidic conditions in the stomach; activates innate immune responses during early steps of infection	247
Flagella	Involved in motility; essential for colonization	248

PAI, pathogenicity island.

Once T cells are activated during an infection, they produce the macrophage-activating factor IFN- $\gamma$ , which has a role in the acute *Salmonella* mouse model in controlling the early phase of bacterial replication<sup>125–127</sup>. It was recently shown that IFN- $\gamma$  has an important role in maintaining and controlling the level of bacterial replication in persistently infected animals, perhaps by stimulating infected macrophages to suppress bacterial replication<sup>106</sup>. Furthermore, people who lack the IL-12 receptor — in whom the T<sub>H</sub>1 response and the production of IFN- $\gamma$  are defective — are more susceptible to infections with *Salmonella* spp.<sup>128</sup> In addition to IFN- $\gamma$  and IL-12, TNF- $\alpha$  might also have a role in maintaining and controlling the level of bacterial replication in persistently infected hosts. Similar to the results seen with *M. tuberculosis*, patients who were treated with anti-TNF- $\alpha$  antibodies developed *Salmonella* septicaemia<sup>129</sup>. HIV-positive individuals develop chronic bacteraemia caused by species of *Salmonella* that do not normally pass beyond the MLNs in healthy individuals<sup>1</sup> — further indicating that an intact adaptive immune system has a role in immunity to *Salmonella*.

*Salmonella* bacteria are probably not passive bystanders in terms of maintaining the balance between clearance and persistence. In this regard, *Salmonella* might have an active role in modulating or even directly manipulating host responses, thereby preventing clearance of intracellular bacteria. Many studies have shown that *S. typhimurium* may limit the *in vivo* proliferation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, despite their activated phenotype<sup>130</sup>. In addition, it has been shown that active *S. typhimurium* infection leads to immunosuppression in mice and causes the production of large amounts of IL-10, which has immunosuppressive activities, and nitric oxide (NO), which has both immunosuppressive and direct antibacterial activities<sup>126,131–133</sup>. Indeed, *S. typhimurium* mutants have been identified that are unable to persist in mice, indicating that they lack

genes that are specifically required for persistence. *S. typhimurium* strains that are deficient for *mig-14*, *virK* and *somA* are able to replicate in unactivated macrophages and establish infections in mice; however, these mutants begin to be cleared in BALB/c mice between 7 and 10 days post-infection<sup>134,135</sup>. The exact functions of the proteins encoded by these genes are not known, but they contribute both to resistance to antimicrobial peptides, which are produced in activated macrophages<sup>136</sup>, and to replication in these cells (I. Bradshaw, D.M.M. and S.F., unpublished observations). The identification of other *S. typhimurium* mutants that are unable to persist in mice will increase our understanding of bacterial mechanisms of persistence.


### Persistent *Helicobacter pylori* infections

During the past 20 years, *H. pylori* has emerged as an important example of a persistent bacterial pathogen. Not only does this bacterium successfully colonize the hostile environment of the human stomach, but the infection regularly persists for the lifetime of the host in the face of a constant, vigorous innate and adaptive immune response. In most infected people, *H. pylori* infection causes superficial chronic gastritis, which is usually clinically asymptomatic, although histologically apparent. However, a significant subset of infected individuals are at risk of the subsequent development of duodenal and peptic ulcers, and 1% of those that are infected will develop adenocarcinoma or lymphoma of the stomach<sup>137</sup>.

Most basic research in the *Helicobacter* field has focused on the study of bacterial virulence determinants (reviewed in REFS 6,138,139; TABLE 3), particularly in the context of their association with severe gastrointestinal sequelae of infection. Although the experimental focus on the association of *H. pylori* with disease is understandable, it is important to point out that the ecological niche for *H. pylori* is progressively lost with the development of ATROPHIC GASTRITIS<sup>140</sup>, and bacteria can only rarely be cultured from seropositive patients with adenocarcinoma. So, from the microbial standpoint, the progression of asymptomatic gastritis to more serious tissue destruction can be viewed as contrary to the best interests of the bacteria in terms of evolutionary success. Therefore, for the purpose of this review, we will shift the focus from the minority of colonized individuals who develop overt disease (~20%) to the majority who remain relatively symptom-free and are likely to represent the reservoir for human infection. We focus here on the bacterial and host characteristics that enable *H. pylori* to colonize its host persistently in the face of a normal immune response.

Most of the studies we will refer to here used animal models. Some *H. pylori* isolates establish long-term infections in rodents or have been adapted to do so by repeated passaging (reviewed in REF 141). Indeed, the limiting factor for the development of animal models of persistent *H. pylori* infection seems to be host specificity rather than lack of persistence. The models that have been used so far vary markedly with respect to disease

ATROPHIC GASTRITIS  
Chronic inflammation of the stomach with degeneration of the mucosa.



**Figure 3 | Persistent *Helicobacter pylori* infection.** Interplay between *H. pylori* factors and the host response leads to chronic gastritis and persistent colonization. *H. pylori* binds to gastric epithelial cells through BabA and other adhesins<sup>249</sup>. In strains that carry the Cag pathogenicity island (Cag-PAI), a type IV secretory apparatus allows translocation of effector molecules such as CagA into the host cell, resulting in the production of interleukin (IL)-8 and other chemokines by epithelial cells. The secreted chemokines lead to the recruitment of polymorphonuclear cells (PMNs), resulting in inflammation. Injected CagA also associates with tight junctions and targets *H. pylori* to them. In the long term, CagA might cause disruption of the epithelial barrier and dysplastic alterations in epithelial-cell morphology. Disruption of junctions by CagA might also cause leakage of nutrients into the mucous layer<sup>245</sup> and entry of bacterial VacA into the submucosa. VacA induces apoptosis in epithelial cells by reducing the mitochondrial transmembrane potential and inducing cytochrome c release, which might also contribute to the disruption of the epithelial barrier. Tumour-necrosis factor- $\alpha$  (TNF- $\alpha$ )-mediated apoptosis may also lead to disruption of the epithelial barrier. The chronic phase of *H. pylori* gastritis links an adaptive lymphocyte response with the initial innate response. Cytokines produced by macrophages, particularly IL-12, activate recruited cells — such as helper T cells (T<sub>H</sub>0, T<sub>H</sub>1 and T<sub>H</sub>2), which respond with a biased T<sub>H</sub>1 response, and B cells. Cytokines also alter the secretion of mucus, which contributes to *H. pylori*-induced disruption of the mucous layer, as they induce changes in gastric-acid secretion and homeostasis. *H. pylori* inhibits the host immune response by blocking the production of nitric oxide (NO) by macrophages and through the ability of VacA to interfere with the IL-2 signalling pathway in T cells (and therefore T-cell activation) by blocking transcription of the genes encoding IL-2 and its receptor, IL-2R (see main text for details). An intracellular pool of *H. pylori* may repopulate the mucous layer after cycles of extracellular clearance. Ig, immunoglobulin.

outcomes, which range from atrophic gastritis, intestinal metaplasia and gastric adenocarcinoma to mucosa-associated lymphoid tissue (MALT) lymphoma, depending on the species used and the genetic background of the host<sup>141</sup>. The identification of bacterial genes that are associated with colonization and persistence of *H. pylori* has been limited by the lack of animal models that support infection by strains for which the genomes have been completely sequenced. This obstacle has recently been overcome by the development of an IL-12-deficient mouse model that is susceptible to infection by the sequenced strain KE26695, which should facilitate whole-genome-based studies of virulence and persistence<sup>142</sup>.

*H. pylori* has developed a number of unique features and strategies that enable it to persist in its host (FIG. 3). These include escape from and neutralization of the

innate and adaptive immune responses; avoidance of a strong proinflammatory response; extensive genetic intrastrain and interstrain diversity; and a partially intracellular lifestyle. In the following sections, we discuss each of these strategies in turn.

***H. pylori* evasion of host immune responses**

**Evasion of innate responses.** NO is a key component of the innate immune system and an effective antimicrobial agent<sup>143</sup>. It is produced by activated macrophages through the action of NOS2, which uses L-arginine as a substrate and is highly expressed both in macrophages infected with *H. pylori*<sup>144</sup> and infected gastric tissues<sup>145</sup>. In a series of elegant experiments using both cultured and peritoneal macrophages, Gobert *et al.* showed that *H. pylori* prevents NO production by host cells by producing the enzyme arginase<sup>146</sup>. Encoded by the gene *rocF*, arginase — which is associated with the bacterial cell envelope — competes with NOS2 for the L-arginine substrate and converts it to urea and L-ornithine, rather than NO. Mutation of the *rocF* gene results in efficient killing of the bacteria in an NO-dependent manner, whereas wild-type bacteria survive under these conditions. Furthermore, the *rocF* mutant is mildly attenuated in its ability to colonize mice<sup>147</sup>, indicating that arginase expression might indeed be important for survival and persistence *in vivo*.

Other bactericidal functions of macrophages also seem to be impaired in the presence of *H. pylori*, and two possible mechanisms for this have been suggested. In one study, Allen *et al.* showed delayed uptake of bacteria into macrophages followed by the formation of megasomes as a result of phagosome fusion. These megasomes protect intracellular bacteria from efficient killing<sup>148</sup>. In a second study using human blood monocytes and polymorphonuclear cells, Ramarao *et al.* showed that *H. pylori* can actively block its own uptake, as well as the uptake of co-cultured bacteria of other species and latex beads<sup>149,150</sup>. Both of these phenotypes depended on the presence of the Cag pathogenicity island (Cag-PAI), which is a 37–40-kb stretch of DNA that encodes a type IV secretion system (TFSS) and which epidemiological studies have linked to more severe disease outcomes<sup>151–153</sup>.

**Evasion of adaptive responses.** *H. pylori* has evolved to subvert not only the innate, but also the adaptive immune response, which is based on MHC-class-II-restricted — and to a lesser degree MHC-class-I-restricted — T cells<sup>154</sup>. Antigen-dependent proliferation of T cells is blocked specifically by *H. pylori*<sup>155</sup> — an effect that is mediated by the virulence factor vacuolating cytotoxin A (VacA)<sup>156,157</sup>. VacA is a 95-kDa, secreted protein that, among other functions, induces cellular vacuolization in epithelial cells<sup>158,159</sup>. VacA has been shown to act as an immunomodulator by interfering with the IL-2 signalling pathway in T cells by blocking Ca<sup>2+</sup> mobilization and the activity of the Ca<sup>2+</sup>/calmodulin-dependent phosphatase calcineurin<sup>156,157</sup>. The secretion of IL-2 and the surface localization of the high-affinity IL-2 receptor (IL-2R) are necessary for

efficient T-cell proliferation and activation. In normal T cells, calcineurin dephosphorylates the transcription factor **NFAT** (for nuclear factor of activated T cells), which then translocates into the nucleus and activates the transcription of several genes that are involved in the immune response. Among these are the genes encoding *IL-2* and *IL-2R $\alpha$* . In T cells that are infected with *VacA*<sup>+</sup> *H. pylori*, however, nuclear translocation of NFAT is blocked, as dephosphorylation is prevented and the downstream genes are not expressed.

Another possible function of *VacA* in subverting the adaptive immune response is its ability to interfere with antigen presentation mediated by MHC class II<sup>160</sup>. After it inserts into the plasma membrane, *VacA* is internalized by endocytosis and reaches the late-endosomal compartment. This compartment is then converted into large acidic vacuoles by the anion-selective channel activity of *VacA*<sup>161,162</sup>. In antigen-presenting cells, the processing of proteins into peptide epitopes, which takes place in the endocytic compartment, is greatly reduced owing to *VacA* activity, indicating that antigen presentation is abrogated in these cells<sup>160</sup>.

The importance of *VacA* in establishing an infection has been corroborated by experiments in mice, which have shown that a null mutation of *vacA* compromises the ability of *H. pylori* to colonize the murine stomach in the presence of the corresponding parental strain<sup>163</sup>. However, the precise effect of *VacA* on cellular and epithelial physiology that facilitates *H. pylori* colonization in the murine stomach is unknown.

### ***H. pylori* suppresses inflammatory responses**

Several lines of evidence indicate that, to allow long-term colonization, there has been selective pressure on *H. pylori* to avoid triggering an intense inflammatory reaction<sup>164</sup>. It has been proposed that high levels of inflammation may lead to loss of gastric glandular structure and function<sup>165</sup> and that *H. pylori* disappears from stomachs that have developed atrophic gastritis<sup>140</sup>. Furthermore, an increased inflammatory reaction — as seen in *IL-10*-knockout mice — is associated with clearance of the bacteria from the stomach within 8 days of the infection<sup>166</sup>. Similarly, increased inflammation due to deletion of the gene encoding PHOX results in a marked reduction in bacterial numbers<sup>167</sup>. All of these findings indicate that, at least in animal models, a strong inflammatory reaction is necessary for the elimination of *H. pylori* and seems to be actively repressed by this bacterium.

But how does *H. pylori* modulate the host inflammatory response? Bacterial lipopolysaccharide (LPS) is the main mediator of inflammation during infections with most Gram-negative bacteria because it activates phagocytic cells, endothelial and epithelial cells and lymphocytes. *H. pylori* LPS, however, has very low biological activity when compared with *Escherichia coli* LPS, at least as measured by its ability to activate macrophages<sup>165</sup>. In fact, the minimum concentration of purified LPS that is required to achieve similar responses was several thousand times greater for *H. pylori* compared with *E. coli* LPS<sup>165</sup>.

The effect of *H. pylori* LPS on gastric epithelial cells — the other main source of proinflammatory cytokines in the stomach besides macrophages — is still unclear. One study has shown that *H. pylori* LPS produced by strains harbouring the Cag-PAI, but not from Cag-PAI mutants, activates Toll-like receptor 4 (**TLR4**) on gastric-pit cells, thereby stimulating the innate immune responses of the gastric mucosa<sup>168</sup>. By contrast, Smith *et al.* reported that TLR2 mediates the proinflammatory effects of *H. pylori* on epithelial cells and show that *H. pylori* LPS is a **TLR2** agonist<sup>169</sup>. These authors suggest that the low level of pathogenicity of *H. pylori* LPS does indeed result from its failure to activate TLR4, the receptor that mediates LPS signalling of most other Gram-negative species<sup>170</sup>.

A recent study has reported similar findings for *H. pylori* flagellins. The two *H. pylori* flagellins — **FlaA** and **FlaB** — were shown to have a markedly reduced potential to activate TLR5 compared with flagellins of other Gram-negative bacteria, such as *FliC* of *S. typhimurium*<sup>171</sup>. The evolution of these unique flagellins, which share extensive amino-acid homology with flagellins from other species that do stimulate TLR5, has been proposed to preserve the essential function of the flagella during chronic colonization while avoiding the activation of the innate immune system<sup>171</sup>.

In a recent study investigating a link between the Cag-PAI and the induction of proinflammatory responses, Philpott *et al.* showed that clinical isolates of *H. pylori* were more likely to colonize mice if they did not harbour the Cag-PAI and were therefore unable to induce such responses in cultured cells<sup>172</sup>. Mouse-adapted variants that lacked the Cag-PAI infected mice at higher levels and had a reduced capacity to induce inflammatory responses *in vitro* compared with the respective parental strains. Taken together, these findings imply that there may be a profound *in vivo* selection against *H. pylori* strains and variants that induce a strong host inflammatory response<sup>172</sup>, at least in the mouse model.

The relative *in vivo* advantages for *H. pylori* with Cag<sup>+</sup> versus Cag<sup>-</sup> phenotypes in human hosts are unclear<sup>173,174</sup>. One study of an individual infected with multiple strains showed recombination between strains resulting in excision of the Cag-PAI and subsequent positive selection of a Cag<sup>-</sup> strain<sup>175</sup>. It is therefore unclear as to how the Cag-PAI benefits the bacteria during a persistent infection; it may be that it is important for a specific stage of colonization, but is dispensable at other stages.

### **Genetic diversity in *H. pylori***

Extensive recombination and a PANMICTIC overall population structure result in substantial genetic diversity among *H. pylori* strains<sup>176–179</sup>. This has been proposed to allow the bacteria to adapt rapidly to changing conditions in their current host as well as to facilitate the colonization of new hosts<sup>180–182</sup>. Although *H. pylori* populations in individuals and even families seem to be clonal, as determined by conventional procedures — such as RANDOMLY AMPLIFIED POLYMORPHIC DNA (RAPD) PCR and

PANMIXIS

Mating without regard to the genetic constitution of the mate.

DNA sequence analysis<sup>179</sup> — more sensitive approaches have indicated that extensive changes can and do occur in a single host over time<sup>183</sup>. For example, fortuitously, additional *H. pylori* isolates were obtained from one patient six years after an isolate of the sequenced strain J99 was first obtained from this individual. These new clinical isolates were subjected to extensive molecular comparisons with the original J99 strain. RAPD PCR and sequencing of several unlinked loci indicated that these isolates were undoubtedly related to the original strain; however, microarray analysis showed differences in genetic content that reflected both acquisitions and losses of genomic DNA<sup>183</sup>. Approximately 3% of J99 loci showed variation between isolates obtained from this individual, compared with 22% of loci when isolates from different individuals were compared<sup>184</sup>. Although most of the open reading frames that were affected represented ‘hypothetical genes’, one was predicted to encode a protein belonging to the *TraG* family, other members of which have been shown to be involved in genetic transfer<sup>185,186</sup>. A putative similar function of *TraG* implies that acquisition of this gene might confer an evolutionary advantage by providing another mechanism through which DNA exchange could occur.

In a recent similar study, three output strains from an experimental infection of Rhesus macaques were compared with the strain that was used for inoculation<sup>187</sup>. All three of the output strains had lost expression of the *babA* gene, which encodes an adhesin that binds to the LEWIS BLOOD GROUP Le<sup>b</sup> antigen<sup>188</sup>. Loss of *babA* expression occurred by two different mechanisms in different isolates. In some cases, *babA* was replaced by the closely related *babB* gene, leading to loss of *babA* and duplication of *babB*. In others, a change in the number of CT repeats in the 5′ coding region of *babA* resulted in a frameshift and subsequent loss of Le<sup>b</sup> adhesion. *H. pylori* therefore uses both antigenic variation and phase variation to regulate *babA* expression (and possibly the expression of other outer-membrane proteins) *in vivo*; however, the significance of this observation in the context of the host immune response remains to be shown.

Another *H. pylori* structure that undergoes phase variation is its LPS, more specifically the Lewis-blood-group determinant of the LPS O-antigen. The on/off statuses of at least five glycosyltransferase genes determine which LPS phase variant is expressed (reviewed in REF. 189). It was initially assumed that mimicry of the Lewis blood group antigens of the host by *H. pylori* would provide a mechanism of immune evasion and adaptation to the host, a concept that was supported by reports describing a link between the Lewis-blood-group phenotype of isolates with the phenotype of the individuals they were derived from (reviewed in REF. 190). However, this concept has been challenged by the isolation of both Le<sup>x</sup>- and Le<sup>y</sup>-expressing strains from the same host and the fact that even high levels of anti-LPS antibodies do not eradicate the organism. It is now assumed that the production of Lewis antigens by *H. pylori* facilitates the colonization of the host by mediating adhesion to gastric epithelial cells<sup>191,192</sup>.

The high degree of diversity that is seen in *H. pylori* is probably facilitated by its natural competence for DNA transformation. In contrast to other bacteria, natural competence in *H. pylori* is not mediated by type IV pili or type IV pilin-like proteins, but by a TFSS that is encoded by the *comB* operon<sup>193,194</sup>. The ComB8, ComB9 and ComB10 proteins correspond to the *Agrobacterium tumefaciens* VirB8, VirB9 and VirB10 proteins and constitute the basic components of a TFSS<sup>193</sup>. *H. pylori* therefore possesses two functionally independent TFSSs — one for protein secretion and translocation into the host cell that is encoded by the Cag-PAI, and one for DNA uptake. In addition, a third cluster of type IV secretion genes was recently discovered that seems to be present in only a subset of strains<sup>195</sup>. The functional significance of this cluster is unknown at present.

The identification of CRYPTIC PLASMIDS in approximately half of all *H. pylori* strains<sup>196</sup> has given rise to speculation that conjugative transfer of novel sequences carried on plasmids could be another means of horizontal gene transfer — and therefore strain diversity — in *H. pylori*. In support of this hypothesis, Hofreuter *et al.* have recently presented evidence that some of these plasmids contain hot spots for site-specific recombination, encode elements from CHROMOSOMAL PLASTICITY ZONES and might be mobilizable<sup>197</sup>. This indicates that exchange of genetic material between these plasmids and the chromosome can occur, and that these plasmids might be mobilized and spread rapidly in the population. So, genetic diversity, which in turn leads to antigenic diversity, might be an important strategy used by *H. pylori* to evade immune surveillance.

### Repopulation of the stomach by *H. pylori*

The gastric mucosa is normally well-protected against bacterial colonization due to the acidic pH of the lumen, the production of mucus and rapid epithelial-cell turnover. It is therefore tempting to speculate that the adoption of a partially intracellular lifestyle by some members of the bacterial population might allow *H. pylori* to achieve long-term persistence. Although there is little evidence to indicate that the bacterium is predominantly an intracellular pathogen, numerous experimental and clinical observations of biopsy specimens support the notion that a subpopulation of *H. pylori* is able to invade epithelial cells both *in vitro*<sup>198,199</sup> and *in vivo*<sup>200–202</sup>.


Using time-lapse video microscopy and gentamicin-protection assays in a cell-culture system, Amieva *et al.* have provided evidence that *H. pylori* residing in multi-vesicular bodies survive in the intracellular milieu for at least 24 hours, remain motile and retain the ability to emerge from the cells to repopulate the extracellular space<sup>199</sup>. Up to several dozen bacteria can be found in one vesicle, indicating that intracellular replication does occur, at least sporadically. These findings indicate that the intracellular niche can potentially function as a ‘hideout’ and sustain the renewal of the population under the unfavourable conditions that are found in the mammalian stomach. Nevertheless, the vast majority of

**RANDOMLY AMPLIFIED POLYMORPHIC DNA (RAPD) PCR**  
A molecular technique used for the classification and comparison of different isolates of the same species. This method uses a randomly chosen oligonucleotide to prime DNA synthesis and results in strain-specific patterns of DNA products.

**LEWIS BLOOD GROUP**  
Antigens of red blood cells, saliva and other body fluids that are specified by the Le gene and react with the antibodies designated anti-Le<sup>a</sup> and anti-Le<sup>b</sup>.

**CRYPTIC PLASMIDS**  
Small, mobilizable genetic elements that can encode virulence factors.

**CHROMOSOMAL-PLASTICITY ZONES**  
Segments of the chromosome that are characterized by their different G+C content, which is a hallmark of horizontally acquired sequences.



**Figure 4 | Balancing protective immunity and immunopathology during persistent bacterial infections.**

The balance between the immune response and infection during persistent infections is important for both the host and the pathogen, with the host switching off the immune response when it becomes more harmful than the presence of the pathogen. This is depicted by the horizontal axis between protection and pathology on either side of the balance. The illustration shows how complex interactions between the pathogen and host lymphocytes and antigen-presenting cells may drive immune responses, with regulatory T cells having an important role in the balance between protection and immunopathology. Host factors involved in the immune response — such as interferon- $\gamma$  (IFN- $\gamma$ ), tumour-necrosis factor- $\alpha$  (TNF- $\alpha$ ), nitric oxide (NO) and the interleukins IL-12 and IL-23 — contribute to both immunopathology and suppression of bacterial persistence. Bacterial persistence is mediated by specific bacterial persistence factors and potentially dysregulated immune responses that could facilitate persistence by contributing to chronic inflammation and low-level tissue injury that facilitates bacterial survival. We postulate that bacterial factors that are important for persistence might have an as-yet-undetermined role in directing this balance by influencing regulatory T cells. TGF- $\beta$ , transforming growth factor- $\beta$ .

*H. pylori* in the stomach are extracellular, highly motile organisms that reside in the mucus overlying the gastric mucosa. How the organism survives here in the presence of high levels of antibody is one of the most poorly understood issues in *H. pylori* pathogenesis. It is equally remarkable that individuals who are cured of infection by antibiotic therapy after decades of colonization are susceptible to re-infection, although at a slightly lower rate<sup>203</sup>.

### Conclusions

Many hypotheses can be proposed for the survival of a population of microorganisms in the presence of immune responses. The organisms could 'hide' inside macrophages within granulomas — as is the case for

*M. tuberculosis* and *S. typhi* — where they are effectively screened from active immune surveillance. The ability of persistent species such as *M. tuberculosis*, *S. typhi*, *Chlamydia* spp. and *Brucella* spp. to modify the intravacuolar environment is a common feature of these bacteria that could clearly favour persistence and evasion of immune responses through reduced surface-antigen presentation or the control of apoptotic pathways<sup>204–208</sup>. Some persistent pathogens might seek an intracellular location at specific times during infection. Indeed, the ability of the mucosal-surface colonizer *H. pylori* to cycle between extracellular and intracellular locations highlights a strategy that may be crucial for some persistent pathogens. Localized subversion of the immune response is also an important feature of persistent bacteria — for example, by interference with cytokine signalling, as described for *M. tuberculosis*, or with innate immune signalling, as described for *H. pylori*.

Finally, the pathological damage that results from continued macrophage activation will at some stage outweigh the immediate risk that is posed by the residual bacteria, and the immune response might turn itself off, allowing bacterial persistence. Regulatory T cells co-expressing CD4 and CD25 markers have been shown to exert this type of control during *Leishmania major* infection<sup>209</sup>. Although there are diverse phenotypes of regulatory T cells, functionally they share the ability to downregulate immune responses. One way that this is achieved is by the secretion of cytokines such as IL-10 and TGF- $\beta$ , which inhibit both T<sub>H</sub>1 and T<sub>H</sub>2 responses *in vivo* and have a role in controlling T-cell responses that are directed against self-antigens<sup>210,211</sup>. Belkaid *et al.* have shown that during persistent infection by *L. major* in the skin, CD4<sup>+</sup>CD25<sup>+</sup> T cells accumulate in the dermis, where they suppress the ability of CD4<sup>+</sup>CD25<sup>-</sup> effector T cells to eliminate the parasite from this site through both IL-10-dependent and IL-10-independent mechanisms<sup>209</sup>. Furthermore, the sterilizing immunity that is achieved in mice with impaired IL-10 activity is followed by loss of immunity to reinfection. Therefore, it is possible that the equilibrium that is established between effector and regulatory T cells in sites of chronic infection might reflect both pathogen and host survival strategies (FIG. 4). Whether regulatory T cells have a role in the mechanisms that are used in persistent *Helicobacter*, *Mycobacteria* and *Salmonella* infections is unknown. However, a high proportion of CD4<sup>+</sup> T cells that are able to release IL-10 can be found in chronic mycobacterial infections<sup>212</sup>, and *S. typhimurium* induces macrophage and splenic IL-10 expression<sup>213</sup>, possibly indicating the presence of regulatory T cells. It was recently shown that regulatory T cells reduce *H. pylori*-induced gastritis in mice, while allowing the bacterium to colonize the mucosa at higher densities<sup>214</sup>, and that *H. pylori*-specific CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells suppress memory T-cell responses to *H. pylori* in infected humans<sup>215</sup>. In line with this observation, *H. pylori* infection of IL-10-knockout mice resulted in more severe gastritis and bacterial clearance after 8 days<sup>166</sup>.

Although we describe some possible mechanisms of pathogen persistence in this review, we actually know very little about how these microorganisms survive for long periods of time in the host in the presence of immunosurveillance. Future applications of genome-based techniques — including array-based analysis of libraries of

bacterial mutants and host expression profiling — as well as laser microdissection, will allow further investigation of the fundamental genetics of bacterial persistence and host immune responses. These findings will hopefully lead to improvements in therapeutic approaches and, perhaps, the elimination of these unwanted companions.

1. Young, D., Hussell, T. & Dougan, G. Chronic bacterial infections: living with unwanted guests. *Nature Immunol.* **3**, 1026–1032 (2002).
2. Fhen, M., Eriksson, S., Clements, M., Bergstrom, S. & Normark, S. J. The basis of persistent bacterial infections. *Trends Microbiol.* **11**, 80–86 (2003).
3. Everhart, J. E. Recent developments in the epidemiology of *Helicobacter pylori*. *Gastroenterol. Clin. North Am.* **29**, 559–578 (2000).
4. Kaufmann, S. H. How can immunology contribute to the control of tuberculosis? *Nature Rev. Immunol.* **1**, 20–30 (2001).
5. Stewart, G. R., Robertson, B. D. & Young, D. B. Tuberculosis: a problem with persistence. *Nature Rev. Microbiol.* **1**, 97–105 (2003).
6. Peek, R. M. & Blaser, M. J. *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nature Rev. Cancer* **2**, 28–37 (2002).
7. Shukla, V. K., Singh, H., Pandey, M., Upadhyay, S. K. & Nath, G. Carcinoma of the gallbladder — is it a sequel of typhoid? *Dig. Dis. Sci.* **45**, 900–903 (2000).
8. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Ravignone, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. *JAMA* **282**, 677–686 (1999).
9. Geijtenbeek, T. B. *et al.* Mycobacteria target DC-SIGN to suppress dendritic cell function. *J. Exp. Med.* **197**, 7–17 (2003).
10. Tailleux, L. *et al.* DC-SIGN is the major *Mycobacterium tuberculosis* receptor on human dendritic cells. *J. Exp. Med.* **197**, 121–127 (2003).
- References 9 and 10 show that DC-SIGN on dendritic cells mediates *M. tuberculosis* entry *in vivo* and might have a role in bacterial persistence and immunity.**
11. Balasubramanian, V., Wiegshaus, E. H., Taylor, B. T. & Smith, D. W. Pathogenesis of tuberculosis: pathway to apical localization. *Tuber. Lung Dis.* **75**, 168–178 (1994).
12. Gedde-Dahl, T. Tuberculous infection in the light of tuberculin matriculation. *Am. J. Hyg.* **56**, 139–214 (1952).
13. Park, D. R. *et al.* The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. *J. Infect. Dis.* **184**, 268–277 (2001).
14. Kulaga, S. *et al.* Molecular epidemiology of tuberculosis in Montreal. *CMAJ* **167**, 353–354 (2002).
15. Adams, D. O. The granulomatous inflammatory response. A review. *Am. J. Pathol.* **84**, 164–191 (1976).
16. Flynn, J. L. & Chan, J. Immunology of tuberculosis. *Annu. Rev. Immunol.* **19**, 93–129 (2001).
17. Peters, W. & Ernst, J. D. Mechanisms of cell recruitment in the immune response to *Mycobacterium tuberculosis*. *Microbes Infect.* **5**, 151–158 (2003).
18. Roach, D. R., Briscoe, H., Baumgart, K., Rathjen, D. A. & Britton, W. J. Tumor necrosis factor (TNF) and a TNF-mimetic peptide modulate the granulomatous response to *Mycobacterium bovis* BCG infection *in vivo*. *Infect. Immun.* **67**, 5473–5476 (1999).
19. Parrish, N. M., Dick, J. D. & Bishai, W. R. Mechanisms of latency in *Mycobacterium tuberculosis*. *Trends Microbiol.* **6**, 107–112 (1998).
20. Manabe, Y. C. & Bishai, W. R. Latent *Mycobacterium tuberculosis* — persistence, patience, and winning by waiting. *Nature Med.* **6**, 1327–1329 (2000).
21. McKinney, J. D. *In vivo* veritas: the search for TB drug targets goes live. *Nature Med.* **6**, 1330–1333 (2000).
22. Cosma, C. L., Sherman, D. R. & Ramakrishnan, L. The secret lives of the pathogenic mycobacteria. *Annu. Rev. Microbiol.* **57**, 641–676 (2003).
23. Russell, D. G. *Mycobacterium tuberculosis*: here today, and here tomorrow. *Nature Rev. Mol. Cell Biol.* **2**, 569–577 (2001).
24. Kouli, A., Herget, T., Klebl, B. & Ullrich, A. Interplay between mycobacteria and host signalling pathways. *Nature Rev. Microbiol.* **2**, 189–202 (2004).
25. Bouley, D. M., Ghori, N., Mercer, K. L., Falkow, S. & Ramakrishnan, L. Dynamic nature of host–pathogen interactions in *Mycobacterium marinum* granulomas. *Infect. Immun.* **69**, 7820–7831 (2001).
26. Timm, J. *et al.* Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. *Proc. Natl Acad. Sci. USA* **100**, 14321–14326 (2003).
- Levels of selected *M. tuberculosis* mRNAs were quantified *in vitro* in axenic culture, *in vivo* in the lungs of mice and in lung specimens obtained from TB patients with active disease. They showed differential expression of bacterial mRNAs associated with iron limitation, alternative carbon metabolism and cellular hypoxia — conditions that are thought to exist within the granulomatous lesions of TB.**
27. Shi, L., Jung, Y. J., Tyagi, S., Gennaro, M. L. & North, R. J. Expression of T<sub>H</sub>1-mediated immunity in mouse lungs induces a *Mycobacterium tuberculosis* transcription pattern characteristic of nonreplicating persistence. *Proc. Natl Acad. Sci. USA* **100**, 241–246 (2003).
28. Schnappinger, D. *et al.* Transcriptional adaptation of *Mycobacterium tuberculosis* within macrophages: insights into the phagosomal environment. *J. Exp. Med.* **198**, 693–704 (2003).
29. Voskuil, M. I. *et al.* Inhibition of respiration by nitric oxide induces a *Mycobacterium tuberculosis* dormancy program. *J. Exp. Med.* **198**, 705–713 (2003).
30. Talaat, A. M., Lyons, R., Howard, S. T. & Johnston, S. A. The temporal expression profile of *Mycobacterium tuberculosis* infection in mice. *Proc. Natl Acad. Sci. USA* **101**, 4602–4607 (2004).
31. Ramakrishnan, L., Federspiel, N. A. & Falkow, S. Granuloma-specific expression of *Mycobacterium* virulence proteins from the glycine-rich PE-PGRS family. *Science* **288**, 1436–1439 (2000).
32. Verreck, F. A. *et al.* Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. *Proc. Natl Acad. Sci. USA* **101**, 4560–4565 (2004).
- Evidence that IL-23, rather than IL-12, might be the main macrophage-generated cytokine responsible for eliciting IFN- $\gamma$  production and host defence against *M. tuberculosis*. This study also showed differential survival of the bacterium in type 1 versus type 2 macrophages.**
33. Casanova, J. L. & Abel, L. Genetic dissection of immunity to mycobacteria: the human model. *Annu. Rev. Immunol.* **20**, 581–620 (2002).
34. Chan, J., Xing, Y., Magliozzo, R. S. & Bloom, B. R. Killing of virulent *Mycobacterium tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. *J. Exp. Med.* **175**, 1111–1122 (1992).
35. MacMicking, J. D. *et al.* Identification of nitric oxide synthase as a protective locus against tuberculosis. *Proc. Natl Acad. Sci. USA* **94**, 5243–5248 (1997).
36. Ehrst, S. *et al.* Reprogramming of the macrophage transcriptome in response to interferon- $\gamma$  and *Mycobacterium tuberculosis*: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. *J. Exp. Med.* **194**, 1123–1140 (2001).
37. MacMicking, J. D., Taylor, G. A. & McKinney, J. D. Immune control of tuberculosis by IFN- $\gamma$ -inducible LRG-47. *Science* **302**, 654–659 (2003).
38. Ting, L. M., Kim, A. C., Cattamanchi, A. & Ernst, J. D. *Mycobacterium tuberculosis* inhibits IFN- $\gamma$  transcriptional responses without inhibiting activation of STAT1. *J. Immunol.* **163**, 3898–3906 (1999).
39. Giacomini, E. *et al.* Infection of human macrophages and dendritic cells with *Mycobacterium tuberculosis* induces a differential cytokine gene expression that modulates T-cell response. *J. Immunol.* **166**, 7033–7041 (2001).
40. Nau, G. J. *et al.* Human macrophage activation programs induced by bacterial pathogens. *Proc. Natl Acad. Sci. USA* **99**, 1503–1508 (2002).
41. Stanley, S. A., Raghavan, S., Hwang, W. W. & Cox, J. S. Acute infection and macrophage subversion by *Mycobacterium tuberculosis* require a specialized secretion system. *Proc. Natl Acad. Sci. USA* **100**, 13001–13006 (2003).
42. Gao, L. Y. *et al.* Requirement for *kasB* in *Mycobacterium* mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. *Mol. Microbiol.* **49**, 1547–1563 (2003).
43. McMurray, D. N. Disease model: pulmonary tuberculosis. *Trends Mol. Med.* **7**, 135–137 (2001).
44. Walsh, G. P. *et al.* The Philippine cynomolgus monkey (*Macaca fascicularis*) provides a new nonhuman primate model of tuberculosis that resembles human disease. *Nature Med.* **2**, 430–436 (1996).
45. Flynn, J. L. *et al.* Non-human primates: a model for tuberculosis research. *Tuberculosis (Edinb.)* **83**, 116–118 (2003).
46. McCune, R. M., Feldmann, F. M., Lambert, H. P. & McDermott, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. *J. Exp. Med.* **123**, 445–468 (1966).
47. Scanga, C. A. *et al.* Reactivation of latent tuberculosis: variations on the Cornell murine model. *Infect. Immun.* **67**, 4531–4538 (1999).
48. Orme, I. M. A mouse model of the recrudescence of latent tuberculosis in the elderly. *Am. Rev. Respir. Dis.* **137**, 716–718 (1988).
49. Rhoades, E. R., Frank, A. A. & Orme, I. M. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent *Mycobacterium tuberculosis*. *Tuber. Lung Dis.* **78**, 57–66 (1997).
50. Rees, R. J. & Hart, P. D. Analysis of the host–parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. *Br. J. Exp. Pathol.* **42**, 83–88 (1961).
51. Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A. & Duncan, K. Evaluation of a nutrient starvation model of *Mycobacterium tuberculosis* persistence by gene and protein expression profiling. *Mol. Microbiol.* **43**, 717–731 (2002).
52. Wayne, L. G. & Sohaskey, C. D. Nonreplicating persistence of *Mycobacterium tuberculosis*. *Annu. Rev. Microbiol.* **55**, 139–163 (2001).
53. Boon, C. & Dick, T. *Mycobacterium bovis* BCG response regulator essential for hypoxic dormancy. *J. Bacteriol.* **184**, 6760–6767 (2002).
54. Dasgupta, N. *et al.* Characterization of a two-component system, *devR-devS*, of *Mycobacterium tuberculosis*. *Tuber. Lung Dis.* **80**, 141–159 (2000).
55. Sherman, D. R. *et al.* Regulation of the *Mycobacterium tuberculosis* hypoxic response gene encoding  $\alpha$ -crystallin. *Proc. Natl Acad. Sci. USA* **98**, 7534–7539 (2001).
56. Dannenberg, A. M., Ando, M. & Shima, K. Macrophage accumulation, division, maturation, and digestive and microbial capacities in tuberculous lesions. 3. The turnover of macrophages and its relation to their activation and antimicrobial immunity in primary BCG lesions and those of reinfection. *J. Immunol.* **109**, 1109–1121 (1972).
57. Chan, K. *et al.* Complex pattern of *Mycobacterium marinum* gene expression during long-term granulomatous infection. *Proc. Natl Acad. Sci. USA* **99**, 3920–3925 (2002).
58. Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Comprehensive identification of conditionally essential genes in mycobacteria. *Proc. Natl Acad. Sci. USA* **98**, 12712–12717 (2001).
59. Sassetti, C. M. & Rubin, E. J. Genetic requirements for mycobacterial survival during infection. *Proc. Natl Acad. Sci. USA* **100**, 12989–12994 (2003).
- References 58 and 59 describe a new microarray-based method for identifying conditionally essential genes in mycobacteria. These studies also identify new persistence mutants using this technique.**
60. McKinney, J. D. *et al.* Persistence of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. *Nature* **406**, 735–738 (2000).
61. Zahrt, T. C. & Deretic, V. *Mycobacterium tuberculosis* signal transduction system required for persistent infections. *Proc. Natl Acad. Sci. USA* **98**, 12706–12711 (2001).
62. Karakousis, P. C., Bishai, W. R. & Dorman, S. E. *Mycobacterium tuberculosis* cell envelope lipids and the host immune response. *Cell. Microbiol.* **6**, 105–116 (2004).



63. Glickman, M. S., Cox, J. S. & Jacobs, W. R. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of *Mycobacterium tuberculosis*. *Mol. Cell* **5**, 717–727 (2000).
64. Cosma, C. L., Humbert, O. & Ramakrishnan, L. Superinfecting mycobacteria home to established tuberculous granulomas. *Nature Immunol.* 27 June 2004 (doi:10.1038/ni1091).
- Used a zebrafish model to show that trafficking of newly infecting mycobacteria into established tuberculous granulomas is directed by mycobacteria present in macrophages.**
65. Caruso, A. M. *et al.* Mice deficient in CD4 T cells have only transiently diminished levels of IFN- $\gamma$ , yet succumb to tuberculosis. *J. Immunol.* **162**, 5407–5416 (1999).
66. van Pinxteren, L. A., Cassidy, J. P., Smedegaard, B. H., Agger, E. M. & Andersen, P. Control of latent *Mycobacterium tuberculosis* infection is dependent on CD8 T cells. *Eur. J. Immunol.* **30**, 3689–3698 (2000).
67. Scanga, C. A. *et al.* Depletion of CD4<sup>+</sup> T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon- $\gamma$  and nitric oxide synthase 2. *J. Exp. Med.* **192**, 347–358 (2000).
68. Serbina, N. V., Liu, C. C., Scanga, C. A. & Flynn, J. L. CD8<sup>+</sup> CTL from lungs of *Mycobacterium tuberculosis*-infected mice express perforin *in vivo* and lyse infected macrophages. *J. Immunol.* **165**, 353–363 (2000).
69. Stenger, S. *et al.* An antimicrobial activity of cytolytic T cells mediated by granulysin. *Science* **282**, 121–125 (1998).
70. Turner, J. *et al.* CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. *Am. J. Respir. Cell Mol. Biol.* **24**, 203–209 (2001).
71. Barnes, P. F. *et al.* Cytokine production at the site of disease in human tuberculosis. *Infect. Immun.* **61**, 3482–3489 (1993).
72. Barnes, P. F. *et al.* Patterns of cytokine production by mycobacterium-reactive human T-cell clones. *Infect. Immun.* **61**, 197–203 (1993).
73. Verbon, A. *et al.* Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. *Clin. Exp. Immunol.* **115**, 110–113 (1999).
74. Turner, J. *et al.* *In vivo* IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. *J. Immunol.* **169**, 6343–6351 (2002).
75. Flynn, J. L. *et al.* Tumor necrosis factor- $\alpha$  is required in the protective immune response against *Mycobacterium tuberculosis* in mice. *Immunity* **2**, 561–572 (1995).
76. Turner, J., Frank, A. A., Brooks, J. V., Marietta, P. M. & Orme, I. M. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. *Immunology* **102**, 248–253 (2001).
77. Kindler, V., Sappino, A. P., Grau, G. E., Piguet, P. F. & Vassalli, P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. *Cell* **56**, 731–740 (1989).
78. Mohan, V. P. *et al.* Effects of tumor necrosis factor- $\alpha$  on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. *Infect. Immun.* **69**, 1847–1855 (2001).
79. Keane, J. *et al.* Tuberculosis associated with infliximab, a tumor necrosis factor- $\alpha$ -neutralizing agent. *N. Engl. J. Med.* **345**, 1098–1104 (2001).
80. Carter, P. B. & Collins, F. M. Peyer's patch responsiveness to *Salmonella* in mice. *J. Reticuloendothel. Soc.* **17**, 38–46 (1975).
81. Vasquez-Torres, A. *et al.* Extraintestinal dissemination of *Salmonella* via CD18-expressing phagocytes. *Nature* **401**, 804–808 (1999).
82. Sinnott, C. R. & Teall, A. J. Persistent gallbladder carriage of *Salmonella typhi*. *Lancet* **1**, 976 (1987).
83. Wain, J. *et al.* Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. *J. Clin. Microbiol.* **39**, 1571–1576 (2001).
84. House, D., Bishop, A., Parry, C., Dougan, G. & Wain, J. Typhoid fever: pathogenesis and disease. *Curr. Opin. Infect. Dis.* **14**, 573–578 (2001).
85. Wain, J. *et al.* Molecular typing of multiple-antibiotic-resistant *Salmonella enterica* serovar Typhi from Vietnam: application to acute and relapse cases of typhoid fever. *J. Clin. Microbiol.* **37**, 2466–2472 (1999).
86. Ledingham, J. C. G. & Arkwright, J. A. *The Carrier Problem in Infectious Disease* (Edward Arnold, London, 1912).
87. Stokes, A. & Clarke, C. A search for typhoid carriers among 800 convalescents. *Lancet* **1**, 566–569 (1912).
88. Levine, M. M., Black, R. E. & Lanata, C. Precise estimation of the numbers of chronic carriers of *Salmonella typhi* in Santiago, Chile, an endemic area. *J. Infect. Dis.* **146**, 724–726 (1982).
89. Vogelsang, T. M. & Boe, J. Temporary and chronic carriers of *Salmonella typhi* and *Salmonella paratyphi* B. *Br. J. Hyg.* **46**, 252–261 (1948).
90. Bao, X., Qiu, J., Yang, N., Mei, L. & Chen, X. Study and preparation of Vi-PHA reagent and its application for detection of *Salmonella typhi* carriers. *Wei Sheng Wu Xue Bao* **32**, 289–295 (1992) (in Chinese).
91. Hormaeche, C. E., Harrington, K. A. & Joysey, H. S. Natural resistance to salmonellae in mice: control by genes within the major histocompatibility complex. *J. Infect. Dis.* **152**, 1050–1056 (1985).
92. Vidal, S. M., Malo, D., Vogan, K., Skamene, E. & Gros, P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. *Cell* **73**, 469–485 (1993).
93. Gruenheid, S., Pinner, E., Desjardins, M. & Gros, P. Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. *J. Exp. Med.* **185**, 717–730 (1997).
94. Vidal, S. *et al.* The *lty/Lsh/Bcg* locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the *Nramp1* gene. *J. Exp. Med.* **182**, 655–666 (1995).
95. Nauciel, C., Ronco, E., Guenet, J. L. & Pla, M. Role of H-2 and non-H-2 genes in control of bacterial clearance from the spleen in *Salmonella typhimurium*-infected mice. *Infect. Immun.* **56**, 2407–2411 (1988).
96. Dunstan, S. J. *et al.* Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. *J. Infect. Dis.* **183**, 261–268 (2001).
- Identifies a genetic association in humans between typhoid fever and MHC class II and III genes. The genes that encode TNF- $\alpha$  and lipophytoxin- $\alpha$ , and alleles of the TNF- $\alpha$  microsatellite, were associated with susceptibility to typhoid fever.**
97. Nauciel, C. Role of CD4<sup>+</sup> T cells and T-independent mechanisms in acquired resistance to *Salmonella typhimurium* infection. *J. Immunol.* **145**, 1265–1269 (1990).
98. Schweitzer, A. N. & Sharpe, A. H. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of T<sub>H</sub>2 but not T<sub>H</sub>1 cytokine production. *J. Immunol.* **161**, 2762–2771 (1998).
99. Mittrucker, H. W., Kohler, A., Mak, T. W. & Kaufmann, S. H. Critical role of CD28 in protective immunity against *Salmonella typhimurium*. *J. Immunol.* **163**, 6769–6776 (1999).
100. Mittrucker, H. W., Raupach, B., Kohler, A. & Kaufmann, S. H. Cutting edge: role of B lymphocytes in protective immunity against *Salmonella typhimurium* infection. *J. Immunol.* **164**, 1648–1652 (2000).
101. Rawlings, D. J. *et al.* Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. *Science* **261**, 358–361 (1993).
102. Thomas, J. D. *et al.* Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. *Science* **261**, 355–358 (1993).
103. Sukupolvi, S., Edelstein, A., Rhen, M., Normark, S. J. & Pfeifer, J. D. Development of a murine model of chronic *Salmonella* infection. *Infect. Immun.* **65**, 838–842 (1997).
104. Stocker, B. A. Aromatic-dependent *Salmonella* as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them. *J. Biotechnol.* **83**, 45–50 (2000).
105. Yamamoto, T. *et al.* Disruption of the genes for CIPXP protease in *Salmonella enterica* serovar Typhimurium results in persistent infection in mice, and development of persistence requires endogenous  $\gamma$ -interferon and tumor necrosis factor- $\alpha$ . *Infect. Immun.* **69**, 3164–3174 (2001).
106. Monack, D. M., Bouley, D. M. & Falkow, S. *Salmonella typhimurium* persists within macrophages in the mesenteric lymph nodes of chronically infected *Nramp1*<sup>+/+</sup> mice and can be reactivated by IFN- $\gamma$  neutralization. *J. Exp. Med.* **199**, 231–241 (2004).
- Established a mouse model of *S. typhimurium* persistence and showed that persisting bacteria reside in MOMA2<sup>+</sup> macrophages within mesenteric lymph nodes and that IFN- $\gamma$  has an important role in maintaining persistence.**
107. Anderson, G. W., Hamblen, A. D. & Smith, H. M. Typhoid carriers. A study of their disease-producing potentialities over a series of years as indicated by a study of cases. *Am. J. Public Health* **26**, 396–405 (1936).
108. Buchwald, D. S. & Blaser, M. J. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi *Salmonella*. *Rev. Infect. Dis.* **6**, 345–356 (1984).
109. Edelman, R. & Levine, M. M. Summary of an international workshop on typhoid fever. *Rev. Infect. Dis.* **8**, 329–349 (1986).
110. Dinbar, A., Altmann, G. & Tulcinsky, D. B. The treatment of chronic biliary salmonella carriers. *Am. J. Med.* **47**, 236–242 (1969).
111. Gaines, S., Sprinz, H., Tully, J. G. & Tigert, W. D. Studies on infection and immunity in experimental typhoid fever. VII. The distribution of *Salmonella typhi* in chimpanzee tissue following oral challenge, and the relationship between the numbers of bacilli and morphologic lesions. *J. Infect. Dis.* **118**, 293–306 (1968).
112. Wigley, P., Berchieri, A., Page, K. L., Smith, A. L. & Barrow, P. A. *Salmonella enterica* serovar Pullorum persists in splenic macrophages and in the reproductive tract during persistent, disease-free carriage in chickens. *Infect. Immun.* **69**, 7873–7879 (2001).
113. Holden, D. W. Trafficking of the *Salmonella* vacuole in macrophages. *Traffic* **3**, 161–169 (2002).
114. Eriksson, S., Lucchini, S., Thompson, A., Rhen, M. & Hinton, J. C. Unravelling the biology of macrophage infection by gene expression profiling of intracellular *Salmonella enterica*. *Mol. Microbiol.* **47**, 103–118 (2003).
115. Richter-Dahlfors, A., Buchan, A. M. J. & Finlay, B. B. Murine salmonellosis studied by confocal microscopy: *Salmonella typhimurium* resides intracellularly inside macrophages and exerts a cytotoxic effect on phagocytes *in vivo*. *J. Exp. Med.* **186**, 569–580 (1997).
116. Monack, D. M. *et al.* *Salmonella* exploits caspase-1 to colonize Peyer's patches in a murine typhoid model. *J. Exp. Med.* **192**, 249–258 (2000).
117. Monack, D. M., Raupach, B., Hromockyj, A. E. & Falkow, S. *Salmonella typhimurium* invasion induces apoptosis in infected macrophages. *Proc. Natl Acad. Sci. USA* **93**, 9833–9838 (1996).
118. van Der Velden, A. W., Lindgren, S. W., Worley, M. J. & Heffron, F. *Salmonella* pathogenicity island 1-independent induction of apoptosis in infected macrophages by *Salmonella enterica* serotype Typhimurium. *Infect. Immun.* **68**, 5702–5709 (2000).
119. Monack, D. M., Detweiler, C. S. & Falkow, S. *Salmonella* pathogenicity island 2-dependent macrophage death is mediated in part by the host cysteine protease caspase-1. *Cell. Microbiol.* (2001).
120. Clements, M. O. *et al.* Polynucleotide phosphorylase is a global regulator of virulence and persistency in *Salmonella enterica*. *Proc. Natl Acad. Sci. USA* **99**, 8784–8789 (2002).
121. Vazquez-Torres, A. *et al.* *Salmonella* pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase. *Science* **287**, 1655–1658 (2000).
122. Hensel, M. *Salmonella* pathogenicity island 2. *Mol. Microbiol.* **36**, 1015–1023 (2000).
123. Wigley, P., Jones, M. A. & Barrow, P. A. *Salmonella enterica* serovar Pullorum requires the *Salmonella* pathogenicity island 2 type III secretion system for virulence and carriage in the chicken. *Avian Pathol.* **31**, 501–506 (2002).
124. Salcedo, S. P., Noursadeghi, M., Cohen, J. & Holden, D. W. Intracellular replication of *Salmonella typhimurium* strains in specific subsets of splenic macrophages *in vivo*. *Cell. Microbiol.* **3**, 587–597 (2001).
125. Nauciel, C. & Espinasse-Maes, F. Role of  $\gamma$ -interferon and tumor necrosis factor- $\alpha$  in resistance to *Salmonella typhimurium* infection. *Infect. Immun.* **60**, 450–454 (1992).
126. Pie, S., Matsiota-Bernard, P., Truffa-Bachi, P. & Nauciel, C.  $\gamma$ -interferon and interleukin-10 gene expression in innately susceptible and resistant mice during the early phase of *Salmonella typhimurium* infection. *Infect. Immun.* **64**, 849–854 (1996).
127. Mastroeni, P. *et al.* Interleukin-12 is required for control of the growth of attenuated aromatic-compound-dependent salmonellae in BALB/c mice: role of  $\gamma$ -interferon and macrophage activation. *Infect. Immun.* **66**, 4767–4776 (1998).
128. Jouanguy, E. *et al.* IL-12 and IFN- $\gamma$  in host defense against mycobacteria and salmonella in mice and men. *Curr. Opin. Immunol.* **11**, 346–351 (1999).
129. Netea, M. G. *et al.* *Salmonella* septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon- $\gamma$  production and Toll-like receptor 4 expression. *Arthritis Rheum.* **48**, 1853–1857 (2003).
130. Mittrucker, H. W., Kohler, A. & Kaufmann, S. H. Characterization of the murine T-lymphocyte response to *Salmonella enterica* serovar Typhimurium infection. *Infect. Immun.* **70**, 199–203 (2002).
131. Eisenstein, T. K., Huang, D., Meissler, J. J. & al-Ramadi, B. Macrophage nitric oxide mediates immunosuppression in infectious inflammation. *Immunobiology* **191**, 493–502 (1994).

132. Pie, S., Truffa-Bachi, P., Pla, M. & Nauciel, C.  $T_H1$  response in *Salmonella typhimurium*-infected mice with a high or low rate of bacterial clearance. *Infect. Immun.* **65**, 4509–4514 (1997).
133. MacFarlane, A. S., Schwacha, M. G. & Eisenstein, T. K. *In vivo* blockage of nitric oxide with aminoguanidine inhibits immunosuppression induced by an attenuated strain of *Salmonella typhimurium*, potentiates *Salmonella* infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen. *Infect. Immun.* **67**, 891–898 (1999).
134. Valdivia, R. H., Cirillo, D. M., Lee, A. K., Bouley, D. M. & Falkow, S. *mig-14* is a horizontally acquired, host-induced gene required for *Salmonella enterica* lethal infection in the murine model of typhoid fever. *Infect. Immun.* **68**, 7126–7131 (2000).
135. Detweiler, C. S., Monack, D. M., Brodsky, I. E., Mathew, H. & Falkow, S. *virK*, *somA* and *rscC* are important for systemic *Salmonella enterica* serovar Typhimurium infection and cationic peptide resistance. *Mol. Microbiol.* **48**, 385–400 (2003).
136. Rosenberger, C. M., Gallo, R. L. & Finlay, B. B. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular *Salmonella* replication. *Proc. Natl Acad. Sci. USA* **101**, 2422–2427 (2004).  
**Demonstrates the expression of cationic peptides in macrophages as an antibacterial effector mechanism against intracellular pathogens. Macrophage expression of the murine cathelicidin-related antimicrobial peptide (CRAMP) impaired *Salmonella* cell division *in vivo*.**
137. Nomura, A., Stemmermann, G. N., Chyow, P. H., Perez-Perez, G. I. & Blaser, M. J. *Helicobacter pylori* infection and the risk for duodenal and gastric ulceration. *Ann. Intern. Med.* **120**, 977–981 (1994).
138. Marshall, B. *Helicobacter pylori*: 20 years on. *Clin. Med.* **2**, 147–152 (2002).
139. Montecucco, C. & Rappuoli, R. Living dangerously: how *Helicobacter pylori* survives in the human stomach. *Nature Rev. Mol. Cell Biol.* **2**, 457–466 (2001).
140. Karnes, W. E. *et al.* Positive serum antibody and negative tissue staining for *Helicobacter pylori* in subjects with atrophic body gastritis. *Gastroenterology* **101**, 167–174 (1991).
141. O'Rourke, J. L. & Lee, A. Animal models of *Helicobacter pylori* infection and disease. *Microbes Infect.* **5**, 741–748 (2003).
142. Hoffman, P. S. *et al.* Development of an interleukin-12-deficient mouse model that is permissive for colonization by a motile KE26695 strain of *Helicobacter pylori*. *Infect. Immun.* **71**, 2534–2541 (2003).
143. Nathan, C. & Shiloh, M. U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. *Proc. Natl Acad. Sci. USA* **97**, 8841–8848 (2000).
144. Wilson, K. T. *et al.* *Helicobacter pylori* stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. *Gastroenterology* **111**, 1524–1533 (1996).
145. Fu, S. *et al.* Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in *Helicobacter pylori* gastritis. *Gastroenterology* **116**, 1319–1329 (1999).
146. Gobert, A. P. *et al.* *Helicobacter pylori* arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. *Proc. Natl Acad. Sci. USA* **98**, 13844–13849 (2001).  
**Shows that *H. pylori* is able to block NOS2-mediated nitric oxide production by expressing the enzyme arginase, which competes for the common substrate L-arginine. Mutation of the corresponding gene results in efficient NO-mediated killing of mutant bacteria by macrophages.**
147. McGee, D. J., Radcliff, F. J., Mendz, G. L., Ferrero, R. L. & Mobley, H. L. *Helicobacter pylori* *rocF* is required for arginase activity and acid protection *in vitro* but is not essential for colonization of mice or for urease activity. *J. Bacteriol.* **181**, 7314–7322 (1999).
148. Allen, L. A., Schlesinger, L. S. & Kang, B. Virulent strains of *Helicobacter pylori* demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages. *J. Exp. Med.* **191**, 115–128 (2000).
149. Ramarao, N., Gray-Owen, S. D., Backert, S. & Meyer, T. F. *Helicobacter pylori* inhibits phagocytosis by professional phagocytes involving type IV secretion components. *Mol. Microbiol.* **37**, 1389–1404 (2000).
150. Ramarao, N. & Meyer, T. F. *Helicobacter pylori* resists phagocytosis by macrophages: quantitative assessment by confocal microscopy and fluorescence-activated cell sorting. *Infect. Immun.* **69**, 2604–2611 (2001).
151. Parsonnet, J., Friedman, G. D., Orentreich, N. & Vogelman, H. Risk for gastric cancer in people with CagA-positive or CagA-negative *Helicobacter pylori* infection. *Gut* **40**, 297–301 (1997).
152. Perez-Perez, G. I., Peek, R. M., Legath, A. J., Heine, P. R. & Graff, L. B. The role of CagA status in gastric and extragastric complications of *Helicobacter pylori*. *J. Physiol. Pharmacol.* **50**, 833–845 (1999).
153. Webb, P. M., Crabtree, J. E. & Forman, D. Gastric cancer, cytotoxin-associated gene A-positive *Helicobacter pylori*, and serum pepsinogens: an international study. The Eurogast Study Group. *Gastroenterology* **116**, 269–276 (1999).
154. Ermak, T. H. *et al.* Immunization of mice with urease vaccine affords protection against *Helicobacter pylori* infection in the absence of antibodies and is mediated by MHC class II-restricted responses. *J. Exp. Med.* **188**, 2277–2288 (1998).
155. Knipp, U., Birkholz, S., Kaup, W., Mahnke, K. & Opferkuch, W. Suppression of human mononuclear cell response by *Helicobacter pylori*: effects on isolated monocytes and lymphocytes. *FEMS Immunol. Med. Microbiol.* **8**, 157–166 (1994).
156. Gebert, B., Fischer, W., Weiss, E., Hoffmann, R. & Haas, R. *Helicobacter pylori* vacuolating cytotoxin inhibits T lymphocyte activation. *Science* **301**, 1099–1102 (2003).
157. Boncristiano, M. *et al.* The *Helicobacter pylori* vacuolating toxin inhibits T cell activation by two independent mechanisms. *J. Exp. Med.* **198**, 1887–1897 (2003).  
**References 156 and 157 show that the vacuolating cytotoxin VacA can act as an immunomodulator by interfering with the IL-2 signalling pathway in T cells. VacA blocks the antigen-dependent proliferation of T cells by inhibiting Ca<sup>2+</sup> mobilization and, subsequently, the activity of the Ca<sup>2+</sup>-dependent phosphatase calcineurin, which in turn inhibits the activation of the transcription factor NFAT.**
158. Cover, T. L. & Blaser, M. J. Purification and characterization of the vacuolating toxin from *Helicobacter pylori*. *J. Biol. Chem.* **267**, 10570–10575 (1992).
159. Montecucco, C., De Bernard, M., Papini, E. & Zoratti, M. *Helicobacter pylori* vacuolating cytotoxin: cell intoxication and anion-specific channel activity. *Curr. Top. Microbiol. Immunol.* **257**, 113–129 (2001).
160. Molinari, M. *et al.* Selective inhibition of IL-dependent antigen presentation by *Helicobacter pylori* toxin VacA. *J. Exp. Med.* **187**, 135–140 (1998).
161. Molinari, M. *et al.* Vacuoles induced by *Helicobacter pylori* toxin contain both late endosomal and lysosomal markers. *J. Biol. Chem.* **272**, 25339–25344 (1997).
162. Ricci, V. *et al.* *Helicobacter pylori* vacuolating toxin accumulates within the endosomal-vacuolar compartment of cultured gastric cells and potentiates the vacuolating activity of ammonia. *J. Pathol.* **183**, 453–459 (1997).
163. Salama, N. R., Otto, G., Tompkins, L. & Falkow, S. Vacuolating cytotoxin of *Helicobacter pylori* plays a role during colonization in a mouse model of infection. *Infect. Immun.* **69**, 730–736 (2001).
164. Blaser, M. J. & Parsonnet, J. Parasitism by the “slow” bacterium *Helicobacter pylori* leads to altered gastric homeostasis and neoplasia. *J. Clin. Invest.* **94**, 4–8 (1994).
165. Perez-Perez, G. I., Shepherd, V. L., Morrow, J. D. & Blaser, M. J. Activation of human THP-1 cells and rat bone marrow-derived macrophages by *Helicobacter pylori* lipopolysaccharide. *Infect. Immun.* **63**, 1183–1187 (1995).
166. Ismail, H. F., Zhang, J., Lynch, R. G., Wang, Y. & Berg, D. J. Role for complement in development of *Helicobacter*-induced gastritis in interleukin-10-deficient mice. *Infect. Immun.* **71**, 7140–7148 (2003).
167. Blanchard, T. G., Yu, F., Hsieh, C. L. & Redline, R. W. Severe inflammation and reduced bacteria load in murine *Helicobacter* infection caused by lack of phagocyte oxidase activity. *J. Infect. Dis.* **187**, 1609–1615 (2003).
168. Kawahara, T. *et al.* Type I *Helicobacter pylori* lipopolysaccharide stimulates toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells. *Infect. Immun.* **69**, 4382–4389 (2001).
169. Smith, M. F. *et al.* Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for *Helicobacter pylori*-induced NF- $\kappa$ B activation and chemokine expression by epithelial cells. *J. Biol. Chem.* **278**, 32552–32560 (2003).
170. Poltorak, A. *et al.* Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in *Tlr4* gene. *Science* **282**, 2085–2088 (1998).
171. Lee, S. K. *et al.* *Helicobacter pylori* flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. *Microbes Infect.* **5**, 1345–1356 (2003).
172. Philpott, D. J. *et al.* Reduced activation of inflammatory responses in host cells by mouse-adapted *Helicobacter pylori* isolates. *Cell. Microbiol.* **4**, 285–296 (2002).
- Investigates the link between the Cag-PAI and induction of proinflammatory responses in the mouse model of *H. pylori* infection. It shows that mouse-adapted variants that lack the Cag-PAI infect mice at higher levels and have a reduced ability to trigger inflammatory responses *in vitro*.**
173. Yamaoka, Y. *et al.* Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive *Helicobacter pylori* strains. *Gut* **41**, 442–451 (1997).
174. Atherton, J. C., Tham, K. T., Peek, R. M., Cover, T. L. & Blaser, M. J. Density of *Helicobacter pylori* infection *in vivo* as assessed by quantitative culture and histology. *J. Infect. Dis.* **174**, 552–556 (1996).
175. Kersulyte, D., Chalkauskas, H. & Berg, D. E. Emergence of recombinant strains of *Helicobacter pylori* during human infection. *Mol. Microbiol.* **31**, 31–43 (1999).
176. Akopyanz, N., Bukanov, N. O., Westblom, T. U. & Berg, D. E. PCR-based RFLP analysis of DNA sequence diversity in the gastric pathogen *Helicobacter pylori*. *Nucleic Acids Res.* **20**, 6221–6225 (1992).
177. Achtman, M. *et al.* Recombination and clonal groupings within *Helicobacter pylori* from different geographical regions. *Mol. Microbiol.* **32**, 459–470 (1999).
178. van Doorn, N. E. *et al.* Genetic DNA fingerprinting of clinical isolates of *Helicobacter pylori* by REP-PCR and restriction fragment end-labelling. *FEMS Microbiol. Lett.* **160**, 145–150 (1998).
179. Suerbaum, S. *et al.* Free recombination within *Helicobacter pylori*. *Proc. Natl Acad. Sci. USA* **95**, 12619–12624 (1998).
180. Blaser, M. J. Ecology of *Helicobacter pylori* in the human stomach. *J. Clin. Invest.* **100**, 759–762 (1997).
181. Blaser, M. J. & Berg, D. E. *Helicobacter pylori* genetic diversity and risk of human disease. *J. Clin. Invest.* **107**, 767–773 (2001).
182. Covacci, A. & Rappuoli, R. *Helicobacter pylori*: molecular evolution of a bacterial quasi-species. *Curr. Opin. Microbiol.* **1**, 96–102 (1998).
183. Israel, D. A. *et al.* *Helicobacter pylori* genetic diversity within the gastric niche of a single human host. *Proc. Natl Acad. Sci. USA* **98**, 14625–14630 (2001).
184. Salama, N. *et al.* A whole-genome microarray reveals genetic diversity among *Helicobacter pylori* strains. *Proc. Natl Acad. Sci. USA* **97**, 14668–14673 (2000).
185. Szpirer, C. Y., Faelen, M. & Couturier, M. Interaction between the RP4 coupling protein TraG and the pBHR1 mobilization protein Mob. *Mol. Microbiol.* **37**, 1283–1292 (2000).
186. Cabezon, E., Saestre, J. I. & de la Cruz, F. Genetic evidence of a coupling role for the TraG protein family in bacterial conjugation. *Mol. Genet.* **254**, 400–406 (1997).
187. Solnick, J. V., Hansen, L. M., Salama, N. R., Boonjakuakul, J. K. & Syvanen, M. Modification of *Helicobacter pylori* outer membrane protein expression during experimental infection of rhesus macaques. *Proc. Natl Acad. Sci. USA* **101**, 2106–2111 (2004).
188. Iver, D. *et al.* *Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging. *Science* **279**, 373–377 (1998).
189. Wang, G., Ge, Z., Flasko, D. A. & Taylor, D. E. Lewis antigens in *Helicobacter pylori*: biosynthesis and phase variation. *Mol. Microbiol.* **36**, 1187–1196 (2000).
190. Appelmelk, B. J., Monteiro, M. A., Martin, S. L., Moran, A. P. & Vandenbroucke-Grauls, C. M. Why *Helicobacter pylori* has Lewis antigens. *Trends Microbiol.* **8**, 565–570 (2000).
191. Osaki, T. *et al.* Establishment and characterisation of a monoclonal antibody to inhibit adhesion of *Helicobacter pylori* to gastric epithelial cells. *J. Med. Microbiol.* **47**, 505–512 (1998).
192. Edwards, N. J. *et al.* Lewis X structures in the O antigen side-chain promote adhesion of *Helicobacter pylori* to the gastric epithelium. *Mol. Microbiol.* **35**, 1530–1539 (2000).
193. Hofreuter, D., Odenbreit, S. & Haas, R. Natural transformation competence in *Helicobacter pylori* is mediated by the basic components of a type IV secretion system. *Mol. Microbiol.* **41**, 379–391 (2001).
194. Hofreuter, D., Odenbreit, S., Henke, G. & Haas, R. Natural competence for DNA transformation in *Helicobacter pylori*: identification and genetic characterization of the *comB* locus. *Mol. Microbiol.* **28**, 1027–1038 (1998).
195. Kersulyte, D. *et al.* Cluster of type IV secretion genes in *Helicobacter pylori*'s plasticity zone. *J. Bacteriol.* **185**, 3764–3772 (2003).
196. Penfold, S. S., Lastovica, A. J. & Elisha, B. G. Demonstration of plasmids in *Campylobacter pylori*. *J. Infect. Dis.* **157**, 850–851 (1988).
197. Hofreuter, D. & Haas, R. Characterization of two cryptic *Helicobacter pylori* plasmids: a putative source for horizontal gene transfer and gene shuffling. *J. Bacteriol.* **184**, 2755–2766 (2002).

198. Kwok, T., Backert, S., Schwarz, H., Berger, J. & Meyer, T. F. Specific entry of *Helicobacter pylori* into cultured gastric epithelial cells via a zipper-like mechanism. *Infect. Immun.* **70**, 2108–2120 (2002).
199. Amieva, M. R., Salama, N. R., Tompkins, L. S. & Falkow, S. *Helicobacter pylori* enter and survive within multivesicular vacuoles of epithelial cells. *Cell. Microbiol.* **4**, 677–690 (2002).
- Provides evidence for a partially intracellular lifestyle of *H. pylori*. The bacterium can be found in cultured epithelial cells residing in multivesicular bodies, where it survives for at least 24 hours and from where it can emerge to repopulate the extracellular space.**
200. Kazi, J. L. *et al.* Ultrastructural study of *Helicobacter pylori*-associated gastritis. *J. Pathol.* **161**, 65–70 (1990).
201. Bode, G., Malfertheiner, P. & Ditschuneit, H. Pathogenetic implications of ultrastructural findings in *Campylobacter pylori* related gastroduodenal disease. *Scand. J. Gastroenterol.* **142**, S25–S39 (1988).
202. Folguet, B., Vicari, F., Guedenet, J. C., De Korwin, J. D. & Marchal, L. Scanning electron microscopic study of *Campylobacter pylori* and associated gastroduodenal lesions. *Gastroenterol. Clin. Biol.* **13**, 65B–70B (1989).
203. Parsonnet, J. What is the *Helicobacter pylori* global reinfection rate? *Can. J. Gastroenterol.* **17**, 46B–48B (2003).
204. Hughes, E. A. & Galan, J. E. Immune response to *Salmonella*: location, location, location? *Immunity* **16**, 325–328 (2002).
205. O'Callaghan, D. *et al.* A homologue of the *Agrobacterium tumefaciens* VirB and *Bordetella pertussis* Ptl type IV secretion systems is essential for intracellular survival of *Brucella suis*. *Mol. Microbiol.* **33**, 1210–1220 (1999).
206. Boschirol, M. L. *et al.* The *Brucella suis* virB operon is induced intracellularly in macrophages. *Proc. Natl Acad. Sci. USA* **99**, 1544–1549 (2002).
207. Byrne, G. I. *et al.* *Chlamydia pneumoniae* expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells. *Infect. Immun.* **69**, 5423–5429 (2001).
208. Fischer, S. F., Schwarz, C., Vier, J. & Hacker, G. Characterization of antiapoptotic activities of *Chlamydia pneumoniae* in human cells. *Infect. Immun.* **69**, 7121–7129 (2001).
209. Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M. & Sacks, D. L. CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells control *Leishmania major* persistence and immunity. *Nature* **420**, 502–507 (2002).
- The persistence of *Leishmania major* in the skin after healing is controlled by an endogenous population of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells. The equilibrium established between effector and regulatory T cells in sites of chronic infection might reflect both parasite and host survival strategies.**
210. Prud'homme, G. J. & Piccirillo, C. A. The inhibitory effects of transforming growth factor- $\beta$ -1 (TGF- $\beta$ 1) in autoimmune diseases. *J. Autoimmun.* **14**, 23–42 (2000).
211. Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O'Garra, A. Interleukin-10 and the interleukin-10 receptor. *Annu. Rev. Immunol.* **19**, 683–765 (2001).
212. Gerosa, F. *et al.* CD4<sup>+</sup> T cell clones producing both interferon- $\gamma$  and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. *Clin. Immunol.* **92**, 224–234 (1999).
213. Nishikawa, F., Yoshikawa, S., Harada, H., Kita, M. & Kita, E. The full expression of the *ity* phenotype in *ityr* mice requires C3 activation by *Salmonella* lipopolysaccharide. *Immunology* **95**, 640–647 (1998).
214. Raghavan, S., Fredriksson, M., Svennerholm, A. M., Holmgren, J. & Suri-Payer, E. Absence of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells is associated with a loss of regulation leading to increased pathology in *Helicobacter pylori*-infected mice. *Clin. Exp. Immunol.* **132**, 393–400 (2003).
- The influence of CD4<sup>+</sup>CD25<sup>+</sup> cells on *H. pylori* colonization in a mouse model of infection was analysed. This showed that these cells reduce immunopathology, possibly by reducing the activation of IFN- $\gamma$ -producing CD4<sup>+</sup> T cells, even at the expense of a higher *H. pylori* load in the gastric mucosa.**
215. Lundgren, A., Suri-Payer, E., Enarsson, K., Svennerholm, A. M. & Lundin, B. S. *Helicobacter pylori*-specific CD4<sup>+</sup>CD25<sup>high</sup> regulatory T cells suppress memory T-cell responses to *H. pylori* in infected individuals. *Infect. Immun.* **71**, 1755–1762 (2003).
216. Saez-Llorens, X. & McCracken, G. H. Bacterial meningitis in children. *Lancet* **361**, 2139–2148 (2003).
217. Salyers, A. & Whitt, D. *Bacterial Pathogenesis — A Molecular Approach* (American Society for Microbiology, Washington, DC, 1994).
218. Park, H. S., Francis, K. P., Yu, J. & Cleary, P. P. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. *J. Immunol.* **171**, 2532–2537 (2003).
219. Lengeling, A., Pfeffer, K. & Balling, R. The battle of two genomes: genetics of bacterial host/pathogen interactions in mice. *Mamm. Genome* **12**, 261–271 (2001).
220. Mastroeni, P. *et al.* Interleukin 18 contributes to host resistance and  $\gamma$ -interferon production in mice infected with virulent *Salmonella typhimurium*. *Infect. Immun.* **67**, 478–483 (1999).
221. Flynn, J. L. *et al.* An essential role for interferon- $\gamma$  in resistance to *Mycobacterium tuberculosis* infection. *J. Exp. Med.* **178**, 2249–2254 (1993).
222. Cooper, A. M. *et al.* Disseminated tuberculosis in interferon- $\gamma$  gene-disrupted mice. *J. Exp. Med.* **178**, 2243–2247 (1993).
223. Cooper, A. M., Magram, J., Ferrante, J. & Orme, I. M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with *Mycobacterium tuberculosis*. *J. Exp. Med.* **186**, 39–45 (1997).
224. Wakeham, J. *et al.* Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by *Mycobacterium bovis* bacille Calmette–Guerin in IL-12-deficient mice. *J. Immunol.* **160**, 6101–6111 (1998).
225. Newport, M. J. *et al.* A mutation in the interferon- $\gamma$ -receptor gene and susceptibility to mycobacterial infection. *N. Engl. J. Med.* **335**, 1941–1949 (1996).
226. Jouanguy, E. *et al.* Interferon- $\gamma$ -receptor deficiency in an infant with fatal bacille Calmette–Guerin infection. *N. Engl. J. Med.* **335**, 1956–1961 (1996).
227. Dorman, S. E. & Holland, S. M. Mutation in the signal-transducing chain of the interferon- $\gamma$ -receptor and susceptibility to mycobacterial infection. *J. Clin. Invest* **101**, 2364–2369 (1998).
228. Yamada, H., Mizumo, S., Horai, R., Iwakura, Y. & Sugawara, I. Protective role of interleukin-1 in mycobacterial infection in IL-1 $\alpha$ / $\beta$  double-knockout mice. *Lab. Invest.* **80**, 759–767 (2000).
229. Sugawara, I. *et al.* Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. *Infect. Immun.* **67**, 2585–2589 (1999).
230. Mitsos, L. M. *et al.* Susceptibility to tuberculosis: a locus on mouse chromosome 19 (*Iti-4*) regulates *Mycobacterium tuberculosis* replication in the lungs. *Proc. Natl Acad. Sci. USA* **100**, 6610–6615 (2003).
231. Tanaka, T. *et al.* Targeted disruption of the *NF-IL6* gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. *Cell* **80**, 353–361 (1995).
232. Everest, P., Roberts, M. & Dougan, G. Susceptibility to *Salmonella typhimurium* infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor- $\alpha$  p55 receptor. *Infect. Immun.* **66**, 3355–3364 (1998).
233. Hess, J., Ladel, C., Miko, D. & Kaufmann, S. H. *Salmonella typhimurium aroA* infection in gene-targeted immunodeficient mice: major role of CD4<sup>+</sup> TCR- $\alpha\beta$  cells and IFN- $\gamma$  in bacterial clearance independent of intracellular location. *J. Immunol.* **156**, 3321–3326 (1996).
234. Jack, R. S. *et al.* Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. *Nature* **389**, 742–745 (1997).
235. Vazquez-Torres, A., Jones-Carson, J., Mastroeni, P., Ischiropoulos, H. & Fang, F. C. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. I. Effects on microbial killing by activated peritoneal macrophages *in vitro*. *J. Exp. Med.* **192**, 227–236 (2000).
236. Sawai, N. *et al.* Role of  $\gamma$ -interferon in *Helicobacter pylori*-induced gastric inflammatory responses in a mouse model. *Infect. Immun.* **67**, 279–285 (1999).
237. El-Omar, E. M. *et al.* Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* **404**, 398–402 (2000).
238. El-Omar, E. M. The importance of interleukin-1 $\beta$  in *Helicobacter pylori* associated disease. *Gut* **48**, 743–747 (2001).
239. El-Omar, E. M. *et al.* Increased risk of noncardia gastric cancer associated with pro-inflammatory cytokine gene polymorphisms. *Gastroenterology* **124**, 1193–1201 (2003).
240. Galmiche, A. *et al.* The N-terminal 34-kDa fragment of *Helicobacter pylori* vacuolating cytotoxin targets mitochondria and induces cytochrome c release. *EMBO J.* **19**, 6361–6370 (2000).
241. Censini, S. *et al.* *cag*, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc. Natl Acad. Sci. USA* **93**, 14648–14653 (1996).
242. Odenbreit, S. *et al.* Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by type IV secretion. *Science* **287**, 1497–1500 (2000).
243. Segal, E. D., Cha, J., Lo, J., Falkow, S. & Tompkins, L. S. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by *Helicobacter pylori*. *Proc. Natl Acad. Sci. USA* **96**, 14559–14564 (1999).
244. Higashi, H. *et al.* SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science* **295**, 683–686 (2002).
245. Amieva, M. R. *et al.* Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. *Science* **300**, 1430–1434 (2003).
246. Guruge, J. L. *et al.* Epithelial attachment alters the outcome of *Helicobacter pylori* infection. *Proc. Natl Acad. Sci. USA* **95**, 3925–3930 (1998).
247. Mobley, H. L. in *Helicobacter pylori: Molecular and Cellular Biology* (eds Achtman, M. & Suerbaum, S.) (Horizon Scientific, Wymondham, 2001).
248. Josenhans, C. & Suerbaum, S. in *Helicobacter pylori: Molecular and Cellular Biology* (eds Achtman, M. & Suerbaum, S.) (Horizon Scientific, Wymondham, 2001).
249. Gerhard, M. *et al.* in *Helicobacter pylori: Molecular and Cellular Biology* (eds Achtman, M. & Suerbaum, S.) (Horizon Scientific, Wymondham, 2001).

#### Acknowledgements

We are grateful to H. Rachman, S. H. E. Kaufmann, C. Cosma and L. Ramakrishnan for sharing unpublished data. We thank S. H. E. Kaufmann, C. Cosma, L. Ramakrishnan, E. Joyce, I. Brodsky, S. Merrell, R. Haas and M. Amieva for critical reading of the manuscript. Research by the authors is supported by the National Institutes of Health, the Ellison Medical Foundation, the Digestive Disease Center (to S.F.) and Deutsche Forschungsgemeinschaft (to A.M.).

#### Competing interests statement

The authors declare no competing financial interests.

#### Online links

##### DATABASES

The following terms in this article are linked online to:

##### Entrez:

<http://www.ncbi.nlm.nih.gov/entrez/>  
*Helicobacter pylori* | IFN- $\gamma$  | IL-2 | IL-2R | IL-10 | IL-12 | IL-23 | LRG-47 | *Mycobacterium marinum* | *Mycobacterium tuberculosis* | NFAT | NOS2 | *Nramp1* | *S. typhi* | *S. typhimurium* | TGF- $\beta$  | TLR2 | TLR4 | TNF- $\alpha$

##### Infectious Disease Information:

<http://www.cdc.gov/ncidod/diseases/index.htm>  
 HIV | salmonellosis | tuberculosis | typhoid fever

SwissProt: <http://ca.expasy.org/sprot/>

*babA* | *babB* | FlaA | FlaB | ICL | *mig-14* | *rocF* | TraG | VacA | *virK*

Access to this interactive links box is free online.